Abbott Laboratories LimitedManufacturer name not currently availableAbiogen PharmaManufacturer name not currently availableAlbert Pharma Inc - " DO NOT USE "Accel Pharmac Inc.Actelion Pharmaceutiques Canada Inc.Adria Laboratories of Canada Ltd.Manufacturer name not currently availableAgouron Pharmaceuticals Canada Inc.Actavis Group PTC ehfManufacturer name not currently availableAkorn Pharmaceuticals Canada Inc. - "DO NOT USE"Manufacturer name not currently availableAltana Pharma Inc.Albert Pharma Inc. - "DO NOT USE"Alcon Canada Inc.Allergan Inc.AllerPharma Inc.Altimed Pharmaceutical CompanyALZA CanadaAmada (Nutritional Products)Amgen Canada Inc.Manufacturer name not currently availableAPP Pharmaceuticals LLCApotex Inc.Astellas Pharma Canada Inc.Astra Pharma Inc.Astra Zeneca - "DO NOT USE"Aton Pharma Inc.Aventis PharmaAventis Pasteur Limited (S8)Advanced Vision Research, Inc. (S8)Axcan Pharma Inc.Axxess Pharma Inc.Ayerst Laboratories, Division of Ayerst, McKenna & HarrisonAstraZenecaBaxter Corporation - Clintec Nutrition Division (S8)Bayer Inc., Health Care DivisionBaker Cummins IncBarr Laboratories Inc.Bausch & Lomb Canada Inc. - "DO NOT USE"Baxter CorporationBayer Inc., Consumer Care DivisionManufacturer name not currently availableBaker Cummins Inc. - "DO NOT USE"Manufacturer name not currently availableBD Consumer HealthcareManufacturer name not currently availableBerlex Canada Inc. - "DO NOT USE"Berlex Canada IncAxcan Pharma Inc.Biogen Idec Canada Inc.Biovail Pharmaceuticals CanadaDraxis Health Inc.Bristol-Myers Squibb Canada Inc. - "DO NOT USE"Bioniche Pharma (Canada) Ltd. (S8)Manufacturer name not currently availableBoehringer-Ingelheim (Canada) Ltd./LteeBoehringer - Mannheim CanadaBoots Pharmaceuticals - "DO NOT USE"Bristol Myers Squibb Canada IncB. Braun Medical Inc. (S8)Bristol-Myers Squibb Canada Inc. Nutritional Div. OttawaBausch & Lomb Canada IncBauch & Lomb Surgical Inc. (S8)Burroughs Wellcome Inc.Byk Canada Inc.Manufacturer name not currently availableCIBA VisionCanderm Pharmacal Ltd./Ltee - "DO NOT USE"Canderm Pharmacal LtdCelgeneManufacturer name not currently availableCiba-Geigy Self Medication ProductsChurch and Dwight Canada Corp.Ciba Pharmaceuticals, Division of Ciba-Geigy Canada Ltd.Chilcott Laboratories-Division of Warner-Lambert Canada Inc.Clark Laboratory - "DO NOT USE"Clintec (Non-Formulary) - " DO NOT USE"Cosmair Canada Inc.Manufacturer name not currently availableManufacturer name not currently availableConnaught Novo Nordisk Canada Inc. - "DO NOT USE"Cobalt Pharmaceuticals Inc.Columbia LaboratoriesPasteur Merieux Connaught CanadaClay-Park Labs Inc.Crystaal Corp.Custom Pharmaceuticals - "DO NOT USE"Manufacturer name not currently availableChauvin Pharmaceuticals Limited (S8)Cytex Pharmaceutical Co.David Bull Laboratories - "DO NOT USE"David Bull Laboratories (Canada) Inc.DC LabsDermik Laboratories Canada Inc.Desbergers LimitedDioptic Laboratories, Division of Akorn Pharmaceuticals CanaL. P. Dey (S8)Dupont Merck Pharma (Endo Canada Division) - "DO NOT USE"Dominion PharmacalDPT Laboratories - "DO NOT USE"Dupont Merck Pharma - "DO NOT USE"Dermtek Pharmaceuticals Ltd.Manufacturer Name currently not availableDrug Trading Company Ltd. - "DO NOT USE"Duchesnay Inc.Du Pont PharmaManufacturer name not currently availableEndo Canada Division Du Pont Merck PharmaManufacturer name not currently availableElan Pharmaceuticals, Inc.Manufacturer name not currently availableEMD Serono Canada Inc.Enzon Inc. (S8)Erfa Canada Inc.Ethypharm Inc.Euro-Pharm International CanadaEvans Medical Ltd.Fabrigen Inc.Faulding Canada Inc.Ferring Inc.Manufacturer name not currently availableFisons Corporation LimitedBoots Pharmaceuticals Ltd.Fournier Pharma Inc.Merck Frosst Canada & Cie, Merck Frosst Canada & Co.Fujisawa Canada Inc.Galderma Canada IncGalderma - "DO NOT USE"Manufacturer name not currently availableManufacturer name not currently availableGenDerm Canada Inc. - "DO NOT USE"Geigy Pharmaceuticals,Division of Ciba-Geigy Canada Ltd.Genmed, A Division of Pfizer Canada Inc.Genpharm Inc.Genentech Inc. - "DO NOT USE"Genzyme - "DO NOT USE"Gilead Sciences Inc.Glaxo Canada Inc.Glenwood Laboratories Canada Ltd. - "DO NOT USE"Glades, Division of Stiefel Canada Inc. - "DO NOT USE"Glenwood Laboratories Canada LtdGlaxo Wellcome Inc.Manufacturer name not currently availableGraceway PharmaceuticalsGlaxoSmithKline Inc., GlaxoSmithKline Consumer Health CareGlaxoSmithKline Shire BiochemGW Pharma LimitedGenzyme Canada Inc.Les Lab Charton, Division of Herdt & Charton - "DO NOT USE"Healthcomm International Inc. (S8)Manufacturer name not currently availableHollister Stier Laboratories LLCHoffmann-La Roche LimitedManufacturer name not currently availableHoechst Marion Roussel Canada Inc.Hoechst Canada Inc.,Pharmaceutical Div.(Hoechst-Roussel CanaManufacturer name not currently availableHome Diagnostics IncFrank W. Horner Inc.Hospira Healthcare Corporation.Hoechst-Roussel Canada Inc.Manufacturer name not currently availableICN Canada LimitedImmunotech Research Ltd.Immunex CorporationInterfalk Canada Inc. - "DO NOT USE"Manufacturer name not currently availableManufacturer name not currently availableIntermune Inc. (S8)Iolab Canada Inc.Manufacturer name not currently availableInsight Pharmaceuticals CorporationIpsen LimitedIvax Laboratories IncorporatedJacobus Pharmaceutical Company Inc.Jamieson Laboratories Ltd.Janssen Pharmaceutica Inc.Manufacturer name not currently availableChiron Canada ULC (S8)JHP Pharmaceuticals LLCJanssen-Ortho Inc.Jouveinal Inc.Jamp Pharma CorporationKabi PharmaciaKey Pharmaceuticals,Div.of Schering Canada Inc.-"DO NOT USE"Manufacturer name not currently availableKnoll Pharma Inc. - "DO NOT USE"Knoll Pharma Inc.Kenral Inc.,Division of The Upjohn Company of CanadaKremers-Urban (Canada) - "DO NOT USE"Manufacturer name not currently availableLaboratoires Fournier S.A.Leda Health Innovations Inc.Lee-Adams Lab.Lederle Division-of Cyanamid Canada Inc.Leo Pharma Inc.Lifescan Canada Ltd.Eli Lilly Canada Inc.LIOH Inc.The Liposome Company Inc. (S8)Linson Pharma Inc.Luitpold Pharmaceuticals Inc.Manufacturer name not currently availablePaul Maney Labs., Division of Canapharm Ind. Inc.MAYNE PHARMA (CANADA) INC.McNeil Consumer Products Co.Manufacturer name not currently availableManufacturer name not currently availableManufacturer name not currently availableManufacturer name not currently availableMeta Pharmaceuticals Inc.Medicis Canada Ltd.Medisense Canada Inc.Medican PharmaMedical Mart Supplies - "DO NOT USE"Merrell Dow Pharmaceuticals (Canada) Inc.Medican Technologies Inc.Merck Frosst Canada Ltd.Merck Frosst/Schering Pharma GPMGI Pharma Inc.Mint Pharmaceuticals Inc.Miles Canada Inc Pharmaceutical Division - "DO NOT USE"Miles Canada Inc.Diagnostic Division - "DO NOT USE"Miles Canada Inc., Pharmaceuticals DivisionMead Johnson NutritionalsManufacturer name not currently availableMead Johnson Canada3M Pharmaceuticals, Division 3M Canada Inc.Medical Mart Supplies LtdMed-O-Gen Medical Inc.Mayne Pharma (Canada) Inc. (S8)Merit Pharmaceuticals - "DO NOT USE"Marion Merrell Dow CanadaMerck Sharp & Dohme Canada, Division of Merck Frosst CanadaMylan Pharmaceuticals ULCManufacturer name not currently availableNadeau Laboratory Ltd.Manufacturer name not currently availableNephro-Tech, Inc. (S8)Nestle Clinical NutritionNova Biomedical Corporation.Novartis Nutrition CorporationNovo Nordisk Canada IncNovopharm Ltd.Novartis Pharma Canada Inc.Manufacturer name not currently availableNutravite Pharmaceuticals Inc.Nordic Laboratories Inc., Marion Merrell Dow (Canada) Inc.Nu-Pharm Inc.Nycomed Canada Inc.Manufacturer name not currently availableOdan Laboratories Ltd.Organon Teknika Canada IncOrganon Sanofi-Synthelabo CanadaOrtho McNeilOmega Laboratories Ltd.OptimaPharma, a Division of Taro Pharmaceuticals Inc.OPI S.A.Orchid HealthcareOrganon Canada Ltd./LteeOrphan Medical Inc. (S8)Manufacturer name not currently availableOryx Pharmaceuticals Inc.Organon Teknika Inc. - "DO NOT USE"Ovation Pharmaceuticals Inc.Paladin Labs Inc.Pathogenesis Canada Ltd.Pharmalab (1982) Inc. (S8)Manufacturer name not currently availableParke-Davis,Division Warner-Lambert Canada Inc.Pro Doc Laboratories - "DO NOT USE"Pendopharm Inc.Perrigo InternationalPfizer Canada Inc.Purdue PharmaPurdue Frederick Inc.Proctor & Gamble Inc.PanGeo Pharma (Canada) Inc.Proctor & Gamble Pharmaceuticals Canada, Inc.Pharmacia Canada Inc.Manufacturer name not currently availablePharmel Inc.Pharmaco Canada Inc. - "DO NOT USE"Pharmaco Canada IncPharmacia & UpjohnPharmascience Inc.Pharmetics Inc. (S8)Pharmavite Lab. - "DO NOT USE"Manufacturer name not currently availablePharmaceutical Partners of CanadaPrempharm Inc.Proval Pharma Inc.Pharmavite CorporationManufacturer name not currently availableQuest Vitamins, Division of Pangeo Health Brands Inc. (S8)Ratiopharm Inc. (DO NOT USE)Ranbaxy Pharmaceuticals Canada Inc.Roberts Pharmaceutical of Canada Inc.Reed & Carnrick,Division of Block Drug Company (Canada) Ltd.Reddy-Cheminor Inc.Dr Reddy's Laboratories Inc.Rhoxalpharma Inc.Rhodiapharm Inc.Laboratoire Riva Inc.Richmond Pharmaceuticals Inc.Manufacturer name not currently availableRichmond Pharmaceuticals IncRivex Pharma Inc.Manufacturer name not currently availableManufacturer Name currently not availableRoche Diagnostics, a division of Hoffmann-La Roche LimitedRougier Pharma, Division of Ratiopharm Inc.Roberts Pharmaceutical - "DO NOT USE"Rhone-Poulenc Rorer Consumer Inc. - "DO NOT USE"Ross Laboratories-Abbott (Nutritional Products)Roussel Canada Inc.(Hoechst-Roussel Canada Inc.)C. A. Roy Limited - "DO NOT USE"Ratiopharm Inc.Rhone-Poulenc Rorer-Ethical DivisionRhone-Poulenc Rorer Consumer Inc.Sabex Inc. - "DO NOT USE"Sandoz Canada Inc. - "DO NOT USE"Sanofi Canada Inc.Sanofi - Synthelabo Canada Inc.Sanofi Aventis PharmaSanofi Winthrop - "DO NOT USE"Shire BioChem Inc.STIEFFEL BCD PHARMAManufacturer name not currently availableSchein PharmaceuticalSchering Canada Inc.Manufacturer name not currently availableManufacturer name not currently availableSchering-Plough Canada Inc.Shoppers Drug MartStanley Pharmaceuticals Ltd.Sandoz Canada Inc.Searle Canada Inc.Sepracor Pharmaceuticals Inc.Manufacturer name not currently availableServier Canada Inc.Shire Human Genetic Therapies Inc.Shire Canada Inc.Sherwood Inc.SHS North AmericaSigma-Tau Pharmaceutical Inc.Sabex 2002 IncSmithKline Beecham Consumer Healthcare.Seaford Pharmaceuticals Inc. (S8)Manufacturer name not currently availableSolvay Kingswood Inc. - "DO NOT USE"Smith Kline Beecham Pharma IncSmith & Nephew Inc.Solvay Kingswood Inc. - "DO NOT USE"Solvay Pharma Inc.Squire Pharmaceuticals Inc.Manufacturer name not currently availableSerono Canada Inc.Sterimax Inc.Sterling HealthStiefel Canada Inc.Manufacturer name not currently availableSun Pharmaceutical IncSwiss Herbal Remedies Ltd.Syntex Inc.SynCare Pharmaceutical Inc.Takeda Pharmaceuticals North America Inc.Tanta Pharmaceutical Co.TAP PharmaceuticalsTaro Pharmaceuticals Inc.Trans Canaderm Inc.Technilab Inc.Therasense Canada Inc.Theramed CorporationThermor Ltd.Tican Pharmaceuticals Ltd.TEVA Pharmaceuticals Industry Ltd.Laboratory Trianon Inc. - "DO NOT USE"3M Pharmaceuticals/3M Canada Inc. - "DO NOT USE"TaroPharma, a Division of Taro Pharmaceuticals Inc.Manufacturer name not currently availableTrillium Health Care Products Inc.Trophic Canada Ltd.UCB Canada Inc.Unimed Canada Inc.The Upjohn Company of CanadaManufacturer name not currently availableManufacturer name not currently availableUnited Therapeutics Corporation (S8)Valeo Pharma Inc.Valeant Canada Ltd.Vita Health Products Inc. (S8)Viva PharmaceuticalsLundbeck Canada Inc.Virco Pharmaceutical (Canada) Inc.Waymar Pharmaceuticals Inc.Manufacturer name not currently availableWampoleWarner Chilcott Company, Inc.Watson Laboratories Inc.Wyeth PharmaceuticalsManufacturer name not currently availableWomen's Capital CorporationWellSpring Pharmaceutical Canada Corp.Whitehall-Robins IncManufacturer name not currently availableWinthrop LaboratoriesWarner-Lambert - "DO NOT USE"Manufacturer name not currently availableWN Pharmaceuticals Ltd.Wockhardt UK Ltd. (S8)Whitehall-Robins Inc. - "DO NOT USE"Manufacturer name not currently availableWestwood Squibb PharmaceuticalsWestcan Pharmaceuticals - "DO NOT USE"Wyeth Ltd.Xenex Laboratories Inc.Manufacturer cannot be identifiedBaxter AG (S8)Manufacturer for Gov't Pharmacy ItemsZeneca Pharma Inc.Zila Pharmaceuticals Inc.Zymcan Pharmaceuticals Inc.ANTIHISTAMINICSCETIRIZINE HYDROCHLORIDE000110mgTabReactineMCL2007-12-19Apo-CetirizineAPX2007-12-19000220mgTabReactineMCL2008-12-23PMS-CetirizinePMS2008-12-23DIPHENHYDRAMINE HCL000325mgCapBenadrylPDA1996-10-01AllerdrylVAL1996-10-01000450mgCapBenadrylPDA1996-10-01AllerdrylVAL1996-10-01KETOTIFEN00051mgTabZaditenSQI2008-11-04Novo-KetotifenNOP2008-11-04LORATADINE000610mgTabClaritinSCP2007-12-19Apo-LoratadineAPX2007-12-19PROMETHAZINE HCL00072mg/mLO/LPMS-PromethazinePMS1996-10-01PhenerganRPR1996-10-01ANTI-INFECTIVE AGENTSANTHELMINTICSMEBENDAZOLE0008100mgTab3.5050VermoxJNO3.50501996-10-01PIPERAZINE ADIPATE0009Gran 2g Pk.7230EntacylSHI.72301999-02-10ANTIBIOTICS ANTIFUNGALSAMPHOTERICIN B0010Inj Pd-50mg Pk69.0000FungizoneBQU69.00001996-10-01FLUCONAZOLE001110mg/mLO/L1.0109Diflucan P.O.S.PFI1.01091999-04-15For the treatment of oral/esophageal candidiasis in immunocompromised patients (e.g. patients with malignancies and transplant patients) who have failed to respond to nystatin or imidazoles and when oral tablets of fluconazole cannot be tolerated. For oral candidiasis, network will limit supply to 2 weeks. For esophageal candidiasis, network will limit supply to 6 weeks.LU Authorization Period: 1 year.For the treatment of patients with disseminated candidiasis when oral tablets of fluconazole cannot be tolerated.For disseminated candidiasis, network will limit supply to 6 weeks.LU Authorization Period: 1 year.For the treatment of patients with cryptococcal meningitis when oral tablets of fluconazole cannot be tolerated.For cryptococcal meningitis (initial treatment), network will limit supply to 12 weeks.LU Authorization Period: 1 year.For the treatment of patients with vulvovaginal candidiasis when oral tablets of fluconazole cannot be tolerated.For vulvovaginal candidiasis, network will limit supply to one dose 150mg (Repeats no more than every 25 days).LU Authorization Period: 1 year.001250mgTab2.48144.9628DiflucanPFI1996-10-01Novo-FluconazoleNOP2.48144.96282003-04-16Apo-FluconazoleAPX2.48144.96281999-09-15Gen-FluconazoleGEN2.48144.96282003-04-16PMS-FluconazolePMS2.48144.96282003-01-30Taro-FluconazoleTAR2.48144.96282004-12-21Co FluconazoleCOB2.48144.96282008-01-150013100mgTab4.40204.4020DiflucanPFI1996-10-01Novo-FluconazoleNOP4.40204.40202003-04-16Apo-FluconazoleAPX4.40204.40201999-09-15Gen-FluconazoleGEN4.40204.40202003-04-16PMS-FluconazolePMS4.40204.40202003-01-30Taro-FluconazoleTAR4.40204.40202004-12-21Co FluconazoleCOB4.40204.40202008-01-15For the treatment of thrush in immunocompromised patients (i.e. patients with malignancies and transplant recipients) who are unresponsive to nystatin or imidazole preparations;LU Authorization Period: 1 year.For the treatment of oroesophageal candidiasis in immunocompromised patients (i.e. patients with malignancies and transplant recipients);LU Authorization Period: 1 year.For patients with disseminated candidiasis;LU Authorization Period: 1 year.For the treatment of acute cryptococcal meningitis.LU Authorization Period: 1 year.KETOCONAZOLE0014200mgTab.9393.9393A low pH is necessary for absorption. Antacids, anticholinergics/antispasmodics, H2-blockers, and omeprazole may decrease absorption. Ketoconazole is a potent inhibitor of hepatic oxidation of drugs and may cause significant elevation of blood levels of astemizole, cisapride, cyclosporine, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of ketoconazole and astemizole, cisapride or terfenadine. Insulin requirements may be reduced. Hepatotoxicity occurs in approximately 1 in 1500 patients treated with ketoconazole for onychomycosis; female gender, pre-existing disease, alcoholism and greater than 2 weeks of therapy are pre-disposing factors.NizoralJAN1.87861.87861996-10-01Novo-KetoconazoleNOP.9393.93932000-01-17Apo-KetoconazoleAPX.9393.93931999-09-15NYSTATIN0015100000U/mLO/L.0592.2368MycostatinBQU1996-10-01Ratio-NystatinRPH.0592.23681997-10-310016500000UTab.1680.5040MycostatinBQU1996-10-01Ratio-NystatinRPH.1680.50401997-10-31TERBINAFINE HCL0017250mgTabLamisilNOV2007-12-19Apo-TerbinafineAPX2007-12-19Novo-TerbinafineNOP2007-12-19PMS-TerbinafinePMS2008-02-12Gen-TerbinafineGEN2007-12-19Co TerbinafineCOB2007-12-19Sandoz TerbinafineSDZ2007-12-19PMS-TerbinafinePMS2009-09-30VORICONAZOLE001850mgTab11.8800VfendPFI11.88002005-09-270019200mgTab47.5000VfendPFI47.50002005-09-27Outpatient continuation of treatment for documented invasive aspergillosis in patients who have demonstrated a clinical response to either oral or parenteral voriconazole. * The first prescription must be written by a physician based at the hospital where the patient was hospitalized. Note: Limited to 3 months of reimbursement.LU Authorization Period: 1 year.ANTIBIOTICS ERYTHROMYCINSErythromycin alone is not adequate for the treatment of H. influenzae infections. It lacks consistently reliable activity against this organism. Erythromycin is a potent inhibitor of hepatic oxidation of some drugs and may cause significant elevation of blood levels of astemizole, carbamazepine, cyclosporine, digoxin, dihydropyridines, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of erythromycin and astemizole or terfenadine.AZITHROMYCIN0020100mg/5mLO/L-15mL Pk8.3205ZithromaxPFI16.63951997-08-28PMS-AzithromycinPMS8.32052007-01-02Novo-Azithromycin PediatricNOP8.32052009-06-230021200mg/5mLO/L-15mL Pk11.7855ZithromaxPFI23.56951997-08-28PMS-AzithromycinPMS11.78552007-01-02Novo-Azithromycin PediatricNOP11.78552009-06-230022200mg/5mLO/L-22.5mL Pk17.6783ZithromaxPFI35.35432009-03-02PMS-AzithromycinPMS17.67832009-03-02Novo-Azithromycin PediatricNOP17.67832009-06-230023250mgTab2.4667ZithromaxPFI5.13071999-04-15Apo-AzithromycinAPX2.46672006-01-24Co-AzithromycinCOB2.46672006-01-24PMS-AzithromycinPMS2.46672006-03-01Sandoz AzithromycinSDZ2.46672006-01-24Novo-AzithromycinNOP2.46672006-01-24Ratio-AzithromycinRPH2.46672006-05-19Gen-AzithromycinGEN2.46672006-08-240024600mgTabZithromaxPFI1998-12-31Co AzithromycinCOB2008-06-27CLARITHROMYCIN0025500mgER Tab2.51445.0288Biaxin XLABB2.51445.02882003-01-300026125mg/5mLPed Gran.28142.8140BiaxinABB.28142.81401997-08-280027250mg/5mLSusp.56005.6000BiaxinABB.56005.60002003-01-300028250mgTab.78611.5722BiaxinABB1.61643.23281996-10-01PMS-ClarithromycinPMS.78611.57222007-10-03Ratio-ClarithromycinRPH.78611.57222007-09-04Gen-ClarithromycinGEN.78611.57222007-09-04Sandoz ClarithromycinSDZ.78611.57222008-08-28Apo-ClarithromycinAPX.78611.57222007-09-040029500mgTabBiaxinABB2007-10-03PMS-ClarithromycinPMS2007-10-03Ratio-ClarithromycinRPH2007-10-03Gen-ClarithromycinGEN2007-10-03Sandoz ClarithromycinSDZ2008-08-28Apo-ClarithromycinAPX2007-10-03ERYTHROMYCIN BASE0030250mgEnt Pel Cap.2205.8820ERYCPFI.2205.88201996-10-01Apo-Erythro E-CAPX1996-10-010031250mgTab.1828.7312ErythromidABB1996-10-01Apo-ErythroAPX.1828.73121996-10-01ERYTHROMYCIN ESTOLATE003225mg/mLO/L.0368.7360IlosoneLIL1996-10-01Novo-Rythro EstolateNOP.0368.73601996-10-01003350mg/mLO/L.07131.4260IlosoneLIL1996-10-01Novo-Rythro EstolateNOP.07131.42601996-10-01ERYTHROMYCIN ETHYLSUCCINATE003440mg/mLO/L.06691.0035EES-200ABB1996-10-01Novo-Rythro Ethyl SuccinateNOP.06691.00351996-10-01003580mg/mLO/L.10131.5195EES-400ABB1996-10-01Novo-Rythro Ethyl SuccinateNOP.10131.51951996-10-010036600mgTab.33631.0089EES-600ABB1996-10-01Apo-Erythro-ESAPX.33631.00891996-10-01ERYTHROMYCIN STEARATE0037250mgTab.2118.8472ErythrocinABB1996-10-01Apo-Erythro-SAPX.2118.84721996-10-010038500mgTab.53901.0780ErythrocinABB.53901.07801996-10-01Apo-Erythro-SAPX.54251.08501996-10-01ANTIBIOTICS PENICILLINSAMOXICILLINThe activity of amoxicillin is essentially identical to ampicillin. However, amoxicillin is more completely absorbed and causes diarrhea less frequently than ampicillin. The only situation where amoxicillin should not be used to replace oral ampicillin is Shigellosis.0039250mgCap.1750.5250NovamoxinNOP.1750.52501996-10-01Apo-AmoxiAPX1996-10-01Nu-AmoxiNXP1996-10-01AmoxilWAY1996-10-01PMS-AmoxicillinPMS2004-04-06Gen-AmoxicillinGEN1999-04-150040500mgCap.34171.0251NovamoxinNOP.34171.02511996-10-01Apo-AmoxiAPX1996-10-01Nu-AmoxiNXP1996-10-01AmoxilWAY1996-10-01PMS-AmoxicillinPMS2004-04-06Gen-AmoxicillinGEN1999-04-15004125mg/mLO/L.0353.5295NovamoxinNOP.0353.52951996-10-01Apo-AmoxiAPX1996-10-01Nu-AmoxiNXP1996-10-01Novamoxin (Sugar Reduced)NOP1996-10-01AmoxilWAY1996-10-01PMS-AmoxicillinPMS2004-04-06004250mg/mLO/L.0540.8100NovamoxinNOP.0540.81001996-10-01Apo-AmoxiAPX1996-10-01Nu-AmoxiNXP1996-10-01Novamoxin (Sugar Reduced)NOP1996-10-01AmoxilWAY1996-10-01PMS-AmoxicillinPMS2004-04-060043125mgTabNovamoxin ChewableNOP2008-11-04Amoxil ChewableAYE2008-11-040044250mgTabNovamoxin ChewableNOP2008-11-04Amoxil ChewableAYE2008-11-04AMOXICILLIN & CLAVULANIC ACIDAmoxicillin/clavulanic acid is not recommended as first line treatment for acute otitis media and sinusitis. Antibiotic resistance (H. influenzae, M. catarrhalis) due to B-lactamase production has caused only a minority of treatment failures with amoxicillin. Amoxicillin/clavulanic acid is first line treatment for infected bites of cat, dog or human.004525mg & 6.25mg/mLO/L.0517.7755ClavulinGSK.11701.75501996-10-01Apo-Amoxi ClavAPX.0517.77552003-01-30Ratio-Aclavulanate 125FRPH.0517.77552003-04-16004650mg & 12.5mg/mLO/L.08691.3035ClavulinGSK.20113.01651996-10-01Apo-Amoxi ClavAPX.08691.30352003-01-30Ratio-Aclavulanate 250FRPH.08691.30352003-04-160047200mg & 28.5mg/5mLSusp.1440Clavulin (BID)GSK.14402000-01-170048400mg & 57mg/5mLSusp.2753Clavulin (BID)GSK.27532000-01-17Apo-Amoxi ClavAPX2008-04-090049250mg & 125mgTab.43651.3095ClavulinGSK1996-10-01Apo-Amoxi ClavAPX.43651.30952001-10-11Ratio-AclavulanateRPH.43661.30982001-10-110050500mg & 125mgTab.66732.0019ClavulinGSK1.48024.44061996-10-01Apo-Amoxi ClavAPX.66732.00192001-10-11Ratio-AclavulanateRPH.66732.00192001-10-110051875mg & 125mgTab1.0009Clavulin (BID)GSK2.22032000-01-17Apo-Amoxi ClavAPX1.00092003-09-04Ratio-AclavulanateRPH1.00092003-09-04Novo-Clavamoxin 875NOP1.00092004-04-06AMPICILLINUse with caution in urinary tract infections as even E. coli is resistant in approximately 20% of cases.0052250mgCap.30711.2284PenbritinAYE1996-10-01Novo-AmpicillinNOP.30711.22841996-10-010053500mgCap.59552.3820PenbritinAYE1996-10-01Novo-AmpicillinNOP.59552.38201996-10-01CLOXACILLIN0054250mgCap.1850.7400OrbeninAYE1996-10-01Novo-CloxinNOP.1850.74001996-10-01Apo-CloxiAPX1996-10-01Nu-CloxiNXP1996-10-010055500mgCap.34981.3992OrbeninAYE1996-10-01Novo-CloxinNOP.34981.39921996-10-01Apo-CloxiAPX1996-10-01Nu-CloxiNXP1996-10-01005625mg/mLO/L.04501.8000Novo-CloxinNOP.04501.80001996-10-01Apo-CloxiAPX1996-10-01Nu-CloxiNXP1996-10-01OrbeninWAY1996-10-01PENICILLIN V (POTASSIUM)005725mg/mLO/L.05351.0700Nadopen-VNDA1996-10-01Apo-Pen V-KAPX.05351.07001996-10-01005860mg/mLO/L.0472.7080VC-K 500LIL2006-06-15Novo-Pen-VK-500NOP.0472.70801996-10-01Apo-Pen V-KAPX1996-10-010059300mgTab.0710.2840Novo-Pen-VK-500NOP.0710.28401996-10-01PVF-K 500FRS1996-10-01Apo-Pen V-KAPX1996-10-01Nu-Pen VKNXP1996-10-01PIPERACILLIN SODIUM & TAZOBACTAM SODIUM00602g & 250mgInj Pd-Vial PkTazocinWYE2008-12-03Piperacillin & Tazobactam for InjectionAPX2008-12-0300613g & 375mgInj Pd-Vial PkTazocinWYE2008-12-03Piperacillin & Tazobactam for InjectionAPX2008-12-0300624g & 500mgInj Pd-Vial PkTazocinWYE2008-12-03Piperacillin & Tazobactam for InjectionAPX2008-12-03PIVAMPICILLINAlthough pivampicillin is administered every 12 hours rather than every 8 hours for amoxicillin, pivampicillin is more expensive than amoxicillin.0063500mgTab.65881.3176PondocillinLEO.65881.31761996-10-01ANTIBIOTICS TETRACYCLINESDOXYCYCLINE HYCLATE0064100mgTabVibra-TabsPFI1996-10-01Apo-Doxy-TabsAPX2009-05-20MINOCYCLINE HCL006550mgCapRatio-MinocyclineRPH2008-01-15Apo-MinocyclineAPX2008-01-15Novo-MinocyclineNOP2008-11-04MinocinSTI2008-01-15Gen-MinocyclineGEN2008-01-15Sandoz MinocyclineSDZ2008-01-15PMS-MinocyclinePMS2008-04-090066100mgCapRatio-MinocyclineRPH2008-01-15Apo-MinocyclineAPX2008-01-15Novo-MinocyclineNOP2008-11-04MinocinSTI2008-01-15Gen-MinocyclineGEN2008-01-15Sandoz MinocyclineSDZ2008-01-15PMS-MinocyclinePMS2008-04-09TETRACYCLINETetracycline use during tooth development (last half of pregnancy and up to age 8) may cause permanent tooth discoloration or enamel hypoplasia. These reactions are more common during long-term use. Tetracyclines should not be used in these groups unless other antibiotics are unlikely to be effective or are contraindicated.0067250mgCap.0549.2196TetracynPFI1996-10-01Apo-TetraAPX.0549.21961996-10-01ANTIBIOTICS OTHER ANTIBIOTICSCEFACLOR0068250mgCap.96972.9091CeclorPHE1.02073.06211996-10-01PMS-CefaclorPMS1997-08-28Apo-CefaclorAPX.96972.90911997-08-28Nu-CefaclorNXP1999-04-15Novo-CefaclorNOP2000-01-170069500mgCap1.93005.7900CeclorPHE2.00406.01201996-10-01PMS-CefaclorPMS1997-08-28Apo-CefaclorAPX1.93005.79001997-08-28Nu-CefaclorNXP1999-04-15Novo-CefaclorNOP2000-01-17007025mg/mLOral Susp.10371.5555CeclorPHE.10891.63351996-10-01PMS-CefaclorPMS1999-04-15Apo-CefaclorAPX.10371.55551999-04-15007150mg/mLOral Susp.18952.8425CeclorPHE.19932.98951996-10-01PMS-CefaclorPMS1999-04-15Apo-CefaclorAPX.18952.84251999-04-150072375mg/5mLOral Susp.2872CeclorPHE.28721996-12-19PMS-CefaclorPMS1999-04-15CEFADROXIL0073500mgCap.84211.6842DuricefBQU.84211.68421996-10-01Novo-CefadroxilNOP.84211.68422000-01-17Apo-CefadroxilAPX.84211.68422000-04-17CEFIXIME007420mg/mLOral Susp.3989SupraxSAV.39891996-10-010075400mgTab3.43003.4300SupraxSAV3.43003.43001996-10-01CEFOXITIN SODIUM00761g/VialInj Pd-1 Vial PkMefoxinMSD2008-06-27Cefoxitin for InjectionORC2008-06-2700772g/VialInj Pd-1 Vial PkMefoxinMSD2008-06-27Cefoxitin for InjectionORC2008-06-27CEFPROZIL0078125mg/5mLOral Susp.0791CefzilBQU.16931996-12-19Apo-CefprozilAPX.07912007-09-04Sandoz CefprozilSDZ.07912008-12-030079250mg/5mLOral Susp.1581CefzilBQU.33851996-12-19Ran-CefprozilRAN.15812007-09-04Apo-CefprozilAPX.15812007-09-04Sandoz CefprozilSDZ.15812008-12-030080250mgTab.8092CefzilBQU1.73271996-12-19Apo-CefprozilAPX.80922007-06-06Ran-CefprozilRAN.80922007-06-06Sandoz CefprozilSDZ.80922008-03-250081500mgTab1.5867CefzilBQU3.39741996-12-19Apo-CefprozilAPX1.58672007-06-06Ran-CefprozilRAN1.58672007-06-06Sandoz CefprozilSDZ1.58672008-03-25CEFTRIAXONE DISODIUM00820.25g/VialInj Pd-1 Vial Pk5.3750RocephinHLR11.28601996-10-01Ceftriaxone Sodium for Injection, BPMAY5.37502007-09-04Ceftriaxone for Injection USPORC5.37502008-08-2800831g/VialInj Pd-1 Vial Pk17.0000RocephinHLR35.70001996-10-01Ceftriaxone Sodium for Injection, BPMAY17.00002007-09-04Ceftriaxone Sodium for InjectionNOP17.00002008-03-25CeftriaxoneSDZ17.50002007-05-04Ceftriaxone for Injection USPORC17.00002008-01-1500842g/VialInj Pd-1 Vial Pk33.5000RocephinHLR68.97001996-10-01Ceftriaxone Sodium for Injection, BPMAY33.50002007-09-04CeftriaxoneSDZ34.48502007-05-04Ceftriaxone for Injection USPORC33.50002008-01-15008510g/VialInj Pd-1 Vial PkRocephinHLR2008-08-28Ceftriaxone for Injection USPAPX2008-08-28CEFUROXIME AXETIL0086125mg/5mLSusp.1748CeftinGSK.17481998-10-210087250mgTab.72371.4474CeftinGSK1.61873.23741998-10-21Ratio-CefuroximeRPH.72371.44742002-04-04Apo-CefuroximeAPX.72371.44742002-04-040088500mgTab1.43372.8674CeftinGSK3.20676.41341998-10-21Ratio-CefuroximeRPH1.43372.86742002-04-04Apo-CefuroximeAPX1.43372.86742002-04-04CEPHALEXIN MONOHYDRATE0089250mgCap.2250.9000CeporexGLA2006-06-15Novo-LexinNOP.2250.90001996-10-010090500mgCap.45001.8000CeporexGLA2006-06-15Novo-LexinNOP.45001.80001996-10-01009125mg/mLPd for Oral Susp.0457.9140KeflexPHE.0457.91401996-10-01Novo-LexinNOP.0457.91401996-10-01PMS-Cephalexin 125PMS1996-10-01009250mg/mLPd for Oral Susp.09481.8960KeflexPHE.09481.89601996-10-01Novo-LexinNOP.09481.89601996-10-01PMS-Cephalexin 250PMS1996-10-010093250mgTab.2250.9000KeflexPHE.2370.94801996-10-01Novo-LexinNOP1996-10-01Apo-CephalexAPX.2250.90001996-10-01Nu-CephalexNXP1996-10-01PMS-CephalexinPMS1998-12-310094500mgTab.45001.8000KeflexPHE.47401.89601996-10-01Novo-LexinNOP1996-10-01Apo-CephalexAPX.45001.80001996-10-01Nu-CephalexNXP1996-10-01PMS-CephalexinPMS1998-12-31CLINDAMYCIN HCL0095150mgCap.38813.1048Dalacin CPFI.80736.45841996-10-01Ratio-ClindamycinRPH.38813.10482000-07-17Novo-ClindamycinNOP.38813.10482000-11-30Apo-ClindamycinAPX.38813.10482002-07-29Gen-ClindamycinGEN.38813.10482004-10-14PMS-ClindamycinPMS.38813.10482008-05-160096300mgCap.7762Dalacin CPFI1.70541996-12-19Ratio-ClindamycinRPH.77622000-07-17Novo-ClindamycinNOP.77622000-11-30Apo-ClindamycinAPX.77622002-07-29Gen-ClindamycinGEN.77622004-10-14PMS-ClindamycinPMS.77622008-04-09CLINDAMYCIN PALMITATE009715mg/mLPd for Oral Susp.1147Dalacin C Flavoured GranulesPFI.11471996-10-01CLINDAMYCIN PHOSPHATE0098300mg/2mLInj Sol-2mL Pk4.5740Clindamycin is well absorbed by the oral route, therefore stepdown therapy from IV to oral is possible.Dalacin CPFI7.49201996-10-01Clindamycin Phosphate Injection USPSDZ4.57402001-03-07SODIUM FUSIDATE0099250mgTab1.1250Fucidin LeoLEO1.12501996-10-01As part of combination therapy, for the treatment of serious infections confirmed on culture to be caused by a strain of S. aureus or coagulase-negative staphylococci likely susceptible to fusidic acid where standard anti-staphylococcal agents are precluded because of allergy, resistance or treatment failure.LU Authorization Period: 1 year.TOBRAMYCIN0100300mg/5mLInh Sol-5mL Pk50.6250TOBINOV50.62502006-10-23TOBRAMYCIN SULFATE010180mg/2mLInj Sol-2mL Pk4.5000NebcinLIL1996-10-01TobramycinSDZ4.50002002-04-04ANTITUBERCULAR AGENTSETHAMBUTOL HCL0102100mgTab.0973MyambutolLED1996-10-01EtibiVAL.09731996-10-010103400mgTab.2711EtibiVAL.27111996-10-01MyambutolWAY1997-02-04ISONIAZID0104300mgTab.0640IsotamineVAL.06401996-10-01PYRAZINAMIDE0105500mgTab.4980TebrazidVAL.49801996-10-01RIFABUTIN0106150mgCap3.9000MycobutinPFI3.90001996-10-01For the prevention of Mycobacterium Avium Intracellular (MAI) in:Patients with a CD4+ cell count less than 200/mm3 with an AIDS-defining diagnosis;LU Authorization Period: 1 year.Patients with a CD4+ cell count less than 100/mm3 without an AIDS-defining diagnosis.LU Authorization Period: 1 year.RIFAMPINExcept when used for prophylaxis in contacts of H. influenzae or N. meningitidis, rifampin should not be used as monotherapy, as bacterial resistance will develop quickly.0107150mgCap.6038RofactVAL.60381996-10-01RifadinSAV.77071996-10-010108300mgCap.9503RofactVAL.95031996-10-01RifadinSAV1.21291999-01-07ANTIVIRALSABACAVIR & LAMIVUDINE & ZIDOVUDINE0109300mg/150mg/300mgTab17.3102For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.TrizivirGSK17.31022003-01-30ABACAVIR SULFATE011020mg/mLO/L.4474For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.ZiagenGSK.44742000-01-170111300mgTab6.8693For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.ZiagenGSK6.86932000-01-17ABACAVIR SULFATE & LAMIVUDINE0112600mg/300mgTab22.7947Note: For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.KivexaGSK22.79472006-06-15ACYCLOVIR200mg/5mLSusp.2450ZoviraxGLW.24501996-10-01200mgTab.9395Nu-AcyclovirNXP.93951997-04-100113200mgTabZoviraxGSK1996-10-01Ratio-AcyclovirRPH1996-10-01Apo-AcyclovirAPX1998-12-31Gen-AcyclovirGEN2001-06-07Novo-AcyclovirNOP2008-01-15400mgTab1.8555Nu-AcyclovirNXP1.85551997-04-100114400mgTabZoviraxGSK1996-10-01Ratio-AcyclovirRPH1996-10-01Apo-AcyclovirAPX1998-12-31Gen-AcyclovirGEN2001-06-07Novo-AcyclovirNOP2008-01-150115800mgTab2.2664ZoviraxGSK5.06921996-10-01Ratio-AcyclovirRPH2.26641996-10-01Nu-AcyclovirNXP2.26641996-12-19Apo-AcyclovirAPX2.26641998-12-31Gen-AcyclovirGEN2.26642001-03-07Novo-AcyclovirNOP2.26642007-01-02In contrast to bacterial infections, viral replication precedes clinical signs and symptoms. Since antiviral agents are only active against replicating viruses, clinical benefit in reducing severity of symptoms and duration of illness is only marginal, at best. Therefore, treatment initiated beyond the stated time frames below is of no value, and treatment of mild cases should be carefully considered, in light of the minimal benefit which will be achieved. In addition, the balance of evidence indicates that the use of acyclovir in normal hosts in an attempt to prevent post-herpetic neuralgia is of no value.Where specified, treatment must begin within the time frames indicated for the product to be reimbursed. There is no benefit from the therapy begun after these time frames.Acyclovir tablets will be reimbursed when prescribed for:Herpes zoster in immunocompetent patients 50 years of age or older, up to 72 hours after appearance of lesions. Dose: 800mg 5 times/day for 7 days.LU Authorization Period: 1 year.Herpes zoster ophthalmicus regardless of age, up to 72 hours after appearance of lesions. Dose: 800mg 5 times/day for 7 days.LU Authorization Period: 1 year.Herpes zoster in immunocompromised patients regardless of age and time elapsed from onset. Dose: 800mg 5 times/day for 7 days.LU Authorization Period: 1 year.Varicella zoster in immunocompetent patients greater than or equal to 12 years of age, up to 24 hours after appearance of lesions. Dose: 20mg/kg/dose (max. 800mg) 4 times/day for 5 days.Network will limit supply up to 7 days and up to 35 tablets.LU Authorization Period: 1 year.AMPRENAVIR011650mgCap.6691For the treatment of protease inhibitor (PI) experienced HIV-infected patients 12 years of age or older, recommended for use with other PIs e.g., ritonavir. Prescriber must be approved for the Facilitated Access mechanism.AgeneraseGSK.66912002-04-040117150mgCap2.0074For the treatment of protease inhibitor (PI) experienced HIV-infected patients 12 years of age or older, recommended for use with other PIs e.g., ritonavir. Prescriber must be approved for the Facilitated Access mechanism.AgeneraseGSK2.00742002-04-04011815mg/mLO/L.2007For the treatment of protease inhibitor (PI) experienced HIV-infected patients 12 years of age or older, recommended for use with other PIs e.g., ritonavir. Prescriber must be approved for the Facilitated Access mechanism.AgeneraseGSK.20072002-04-04ATAZANAVIR SULFATE0119150mgCap10.3655For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.ReyatazBQU10.36552004-11-040120200mgCap10.4010For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.ReyatazBQU10.40102004-11-04DARUNAVIR0121300mgTab7.1690For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism. In combination with ritonavir, as part of a HIV treatment regimen for treatment-experienced adult patients who have demonstrated failure to at least 2 Protease Inhibitors. PrezistaJNO7.16902007-05-04DELAVIRDINE MESYLATE0122100mgTab.7178For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.RescriptorPFI.71781999-04-15DIDANOSINE0123125mgEnteric Coated Cap3.3777Note: For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.Videx ECBQU3.37772006-10-230124200mgEnteric Coated Cap5.4040Note: For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.Videx ECBQU5.40402006-10-230125250mgEnteric Coated Cap6.7550Note: For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.Videx ECBQU6.75502006-10-230126400mgEnteric Coated Cap10.8300Note: For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.Videx ECBQU10.83002006-10-23EFAVIRENZ012750mgCap1.1717For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.SustivaBQU1.17171999-09-150128200mgCap4.6861For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.SustivaBQU4.68611999-09-150129600mgTab14.0583For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.SustivaBQU14.05832003-09-04EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE0130600mg/300mg/200mgTab39.1083For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.AtriplaBQU39.10832008-08-28EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE0131200mg & 300mgTab25.0500Note: For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.TruvadaGIL25.05002007-09-04ETRAVIRINE0132100mgTab5.4500Note: For use in combination with an optimized regimen, for the treatment of HIV-1 infection in treatment-experienced adult patients who have failed prior anti-retroviral therapies and have HIV-1 strains resistant to multiple antiretroviral agents, including protease inhibitors (PIs) and other non-nucleoside reverse transcriptase inhibitors (NNRTIs). Note: For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanismIntelenceJNO5.45002009-01-30FAMCICLOVIR0133125mgTabFamvirNOV2007-09-04PMS-FamciclovirPMS2007-10-03Sandoz FamciclovirSDZ2007-09-04Apo-FamciclovirAPX2007-09-04Co FamciclovirCOB2008-12-230134250mgTabFamvirNOV2007-09-04PMS-FamciclovirPMS2007-10-03Sandoz FamciclovirSDZ2007-09-04Apo-FamciclovirAPX2007-09-04Co FamciclovirCOB2008-12-230135500mgTab3.2026FamvirNOV6.76241996-10-01PMS-FamciclovirPMS3.20262007-03-09Sandoz FamciclovirSDZ3.20262007-01-02Apo-FamciclovirAPX3.20262007-04-02Co FamciclovirCOB3.20262008-12-23Herpes zoster in patients 50 years of age or older, up to 72 hours* after appearance of lesions. Dose: 500mg 3 times/day for 7 days.*The patient must begin treatment within the time frame specified for the product to be reimbursed. There is no benefit from the therapy begun after this time frame.Network will limit supply to 7 days and 21 tablets.LU Authorization Period: 1 year.FOSAMPRENAVIR CALCIUM013650mg/mLOral Susp.5790For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.TelzirGSK.57902009-01-300137700mgTab7.9200Note: For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.TelzirGSK7.92002006-01-12GANCICLOVIR SODIUM0138500mg/VialPd Inj-10mL Pk41.2140CytoveneHLR41.21402007-01-02For the treatment of CMV retinitis secondary to AIDS and other immunosuppressive syndromes.LU Authorization Period: 1 year.INDINAVIR0139200mgCap1.3467For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.CrixivanMFC1.34671996-12-190140400mgCap2.6933For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.CrixivanMFC2.69331996-12-19LAMIVUDINE014110mg/mLO/L.3139For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism. Reimbursement will not be provided for the treatment of hepatitis.3TCGSK.31391996-10-010142150mgTab4.8358For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism. Reimbursement will not be provided for the treatment of hepatitis.3TCGSK4.83581996-10-010143300mgTab9.6717For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism. Reimbursement will not be provided for the treatment of hepatitis3TCGSK9.67172004-07-20LAMIVUDINE & ZIDOVUDINE0144150mg & 300mgTab10.4412For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.CombivirGSK10.44121999-09-15LOPINAVIR & RITONAVIR014580mg/mL & 20mg/mLO/L2.1245For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.KaletraABB2.12452001-10-110146100mg & 25mgTab2.7002For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.KaletraABB2.70022009-04-010147200mg & 50mgTab5.4004Note: For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.KaletraABB5.40042007-09-04NELFINAVIR MESYLATE0148250mgTab1.8200For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.ViraceptPFI1.82001999-04-150149625mgTab4.5500For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.ViraceptPFI4.55002005-05-25NEVIRAPINE0150200mgTab4.9383For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.ViramuneBOE4.93831999-04-15OSELTAMIVIR PHOSPHATE015175mgCap3.9000TamifluHLR3.90002003-04-16For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B.Network will limit supply to 6 weeks.LU Authorization Period: 1 year.For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.Network will limit supply to 5 days.*The outbreak must be confirmed by Public Health.LU Authorization Period: 1 year.RITONAVIR0152100mgCap1.4468For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.Norvir SECABB1.44682000-02-16015380mg/mLO/L1.1698For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.NorvirABB1.16981996-12-19SAQUINAVIR MESYLATE0154200mgCap1.8200For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.InviraseHLR1.82001996-10-010155200mgCap1.0557For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.FortovaseHLR1.05572000-07-170156500mgTab4.2000Note: For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.InviraseHLR4.20002007-01-02STAVUDINE015715mgCap4.1185For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.ZeritBQU4.11851996-12-19015820mgCap4.2818For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.ZeritBQU4.28181996-12-19015930mgCap4.4672For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.ZeritBQU4.46721996-12-19016040mgCap4.6305For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.ZeritBQU4.63051996-12-19TENOFOVIR DISOPROXIL0161300mgTab16.7376Note: For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access mechanism.VireadGIL16.73762007-01-02VALACYCLOVIR0162500mgTab1.6962ValtrexGSK3.39241996-12-19Apo-ValacyclovirAPX1.69622008-08-28PMS-ValacyclovirPMS1.69622008-08-28Herpes zoster in patients 50 years of age or older, up to 72 hours* after appearance of lesions. Dose: 1 gram 3 times/day for 7 days.*The patient must begin treatment within the time frame specified for the product to be reimbursed. There is no benefit from the therapy begun after this time frame.Network will limit supply to 7 days and 42 capsules.LU Authorization Period: 1 year.VALGANCICLOVIR0163450mgTab22.4100ValcyteHLR22.41002003-04-16For the treatment of CMV retinitis in patients with AIDS.LU Authorization Period: 1 year.ZIDOVUDINE0164100mgCapRetrovirGLW2009-06-23Apo-ZidovudineAPX2009-06-23PLASMODICIDES (ANTIMALARIALS)CHLOROQUINE PHOSPHATE0165250mgTab.3208Novo-ChloroquineNOP.32081996-10-01AralenSAO1996-10-01HYDROXYCHLOROQUINE SULFATE0166200mgTab.2620PlaquenilSAV.58931996-10-01Apo-HydroxyquineAPX.26202003-09-04Gen-HydroxychloroquineGEN.26202004-07-20SULFONAMIDESSULFASALAZINE0167500mgEnt Tab.2816PMS-Sulfasalazine-E.C.PMS.28161996-10-01SalazopyrinPFI.33131996-10-010168500mgTab.1804PMS-SulfasalazinePMS.18041996-10-01SalazopyrinPFI.21221996-10-01TRICHOMONACIDESMETRONIDAZOLE0169500mgCap.42501.2750PMS-MetronidazolePMS.42501.27501996-10-01FlagylSAV.93712.81131996-10-01Apo-MetronidazoleAPX.42501.27502004-07-200170250mgTab.0595.1785Apo-MetronidazoleAPX.0595.17851996-10-01FlagylRPP2001-02-28URINARY ANTI-INFECTIVESNITROFURANTOINNitrofurantoin macrocrystals may be better tolerated. Avoid use of nitrofurantoin during the last 6 weeks of pregnancy. Use with caution in patients with renal impairment.017150mgCap.31871.2748MacrodantinPGP1996-10-01Novo-FurantoinNOP.31871.27481998-12-310172100mgCap.61102.4440MacrodantinPGP1996-10-01Novo-FurantoinNOP.61102.44401998-12-31017350mgTab.1670.6680NifuranMAN2006-06-15Apo-NitrofurantoinAPX.1670.66801996-10-010174100mgTab.2227.8908NifuranMAN2006-06-15Apo-NitrofurantoinAPX.2227.89081996-10-01NITROFURANTOIN MONO/MICRO CRYSTALS0175100mgCap.6903MacroBIDPGP.69031996-12-19MISCELLANEOUS ANTI-INFECTIVESCEFEPIME01761gInj Pd-Vial PkMaxipimeBQU2009-05-20Cefepime for InjectionAPX2009-05-2001772gInj Pd-Vial PkMaxipimeBQU2009-05-20Cefepime for InjectionAPX2009-05-20CIPROFLOXACINCiprofloxacin is not intended for the treatment of asymptomatic bacteriuria in the absence of risk factors. Avoid use in pregnancy and children < 18 years of age. Ciprofloxacin inhibits theophylline clearance and also affects phenytoin kinetics. Theophylline doses should be decreased and blood levels of phenytoin or theophylline monitored when either of these drugs is used concomitantly with ciprofloxacin.017810g/100mLOral Susp.55825.5820CiproBAY.55825.58202001-03-070179250mgTab1.11052.2210CiproBAY2.47424.94841996-10-01Novo-CiprofloxacinNOP1.11052.22102004-07-20Apo-CiprofloxAPX1.11052.22102004-07-20Gen-CiprofloxacinGEN1.11052.22102004-07-20Ratio-CiprofloxacinRPH1.11052.22102004-07-20Co-CiprofloxacinCOB1.11052.22102004-07-20PMS-CiprofloxacinPMS1.11052.22102004-07-20Sandoz CiprofloxacinSDZ1.11052.22102004-07-20Taro-CiprofloxacinTAR1.11052.22102006-06-14Ran-CiprofloxacinRAN1.11052.22102006-01-24Ran-CiprofloxRAN1.11052.22102008-03-250180500mgTab1.25292.5058CiproBAY2.79155.58301996-10-01Novo-CiprofloxacinNOP1.25292.50582004-07-20Apo-CiprofloxAPX1.25292.50582004-07-20Gen-CiprofloxacinGEN1.25292.50582004-07-20Ratio-CiprofloxacinRPH1.25292.50582004-07-20Co-CiprofloxacinCOB1.25292.50582004-07-20PMS-CiprofloxacinPMS1.25292.50582004-07-20Sandoz CiprofloxacinSDZ1.25292.50582004-07-20Taro-CiprofloxacinTAR1.25292.50582006-06-14Ran-CiprofloxacinRAN1.25292.50582006-01-24Ran-CiprofloxRAN1.25292.50582008-03-250181750mgTab2.36314.7262CiproBAY5.111810.22361996-10-01Novo-CiprofloxacinNOP2.36314.72622004-07-20Apo-CiprofloxAPX2.36314.72622004-07-20Gen-CiprofloxacinGEN2.36314.72622004-07-20Ratio-CiprofloxacinRPH2.36314.72622004-07-20Co-CiprofloxacinCOB2.36314.72622004-07-20PMS-CiprofloxacinPMS2.36314.72622004-07-20Sandoz CiprofloxacinSDZ2.36314.72622004-07-20Ran-CiprofloxacinRAN2.36314.72622006-01-24Ran-CiprofloxRAN2.36324.72642008-03-25For the treatment of patients with:SST/BJ (Gram negative bacteria): Skin/soft tissue and bone/joint infection due to gram negative bacteria; severe diabetic foot infection; severe otitis externa; decubitus ulcers.LU Authorization Period: 1 year.GU Tract: Urinary tract infection/prostatitis/epididymitis caused by (suspected or documented) Pseudomonas; sexually transmitted diseases.LU Authorization Period: 1 year.COPD with risk: Acute bacterial exacerbation of chronic obstructive pulmonary disease (COPD) with risk factors*; bronchiectasis; pneumonic illness with cystic fibrosis.*Risk factors include: poor pulmonary lung function (FEV1 below 50% predicted level), age over 65 years, co-morbid medical illness (congestive heart failure, diabetes, chronic renal failure, chronic liver disease), chronic corticosteroid use, malnutrition, prolonged duration of disease or 4 or more exacerbations per year.LU Authorization Period: 1 year.Step-Down: Step-down therapy after parenteral therapy or hospital/emergency department discharge; febrile neutropenia.LU Authorization Period: 1 year.GI: Traveller's diarrhea; enteric fever syndromes; Crohn's disease.LU Authorization Period: 1 year.For the prophylaxis or treatment of B. anthracis exposure.LU Authorization Period: 1 year.Exceptional cases of allergy or intolerance to all other appropriate therapies.LU Authorization Period: 1 year.CIPROFLOXACIN HCL & CIPROFLOXACIN BASE0182500mgER Tab2.9882Cipro XLBAY2.98822005-02-22For patients with uncomplicated urinary tract infections (acute cystitis) who have failure, intolerance or hypersensitivity to all formulary antibiotic alternatives that are listed as General Benefits.LU Authorization Period: 1 year.01831000mgER Tab2.9882Cipro XLBAY2.98822005-02-22For patients with complicated urinary tract infections or acute uncomplicated pyelonephritis who have failure, intolerance or hypersensitivity to all formulary antibiotic alternatives that are listed as General Benefits.LU Authorization Period: 1 year.LEVOFLOXACIN0184250mgTab2.2200LevaquinJNO4.73321999-09-15Novo-LevofloxacinNOP2.22002005-01-25PMS-LevofloxacinPMS2.22002009-09-30Apo-LevofloxacinAPX2.22002009-09-30Sandoz LevofloxacinSDZ2.36662009-09-30Gen-LevofloxacinGEN2.22002009-09-30Co LevofloxacinCOB2.22002009-09-300185500mgTab2.5050LevaquinJNO5.34101999-09-15Novo-LevofloxacinNOP2.50502005-01-25PMS-LevofloxacinPMS2.50502009-09-30Apo-LevofloxacinAPX2.50502009-09-30Sandoz LevofloxacinSDZ2.67052009-09-30Gen-LevofloxacinGEN2.50502009-09-30Co LevofloxacinCOB2.50502009-09-30For the treatment of patients with:CAP with co-morbidity: Community acquired pneumonia with co-morbid illnesses or failure to first-line therapy.LU Authorization Period: 1 year.COPD with risk: Acute bacterial exacerbation of chronic obstructive pulmonary disease (COPD) with risk factors*; bronchiectasis.*Risk factors include: poor pulmonary lung function (FEV1 below 50% predicted level), age over 65 years, co-morbid medical illness (congestive heart failure, diabetes, chronic renal failure, chronic liver disease), chronic corticosteroid use, malnutrition, prolonged duration of disease or 4 or more exacerbations per year.LU Authorization Period: 1 year.Step-Down: Step-down therapy after parenteral therapy or hospital / emergency department discharge.LU Authorization Period: 1 year.Exceptional cases of allergy or intolerance to all other appropriate therapies.LU Authorization Period: 1 year.0186750mgTabLevaquinJNO2009-09-30Novo-LevofloxacinNOP2009-09-30PMS-LevofloxacinPMS2009-09-30Co LevofloxacinCOB2009-09-30Apo-LevofloxacinAPX2009-09-30LINEZOLID0187600mgTab70.6390ZyvoxamPFI70.63902003-01-30For the treatment of patients with:Methicillin-resistant Staphylococcus species (MRSA, MRSE) infections* in patients who are intolerant or have failed vancomycin therapy, or have contraindications to venous access.LU Authorization Period: 1 year.Vancomycin resistant Enterococcus species (VRE) infections* in patients switching from IV linezolid.LU Authorization Period: 1 year.Step-down therapy for the treatment of methicillin-resistant Staphylococcus species or vancomycin resistant Enterococcus species (VRE) infections* after parenteral therapy or hospital/ emergency department discharge.* Infections must be documented and culture proven. Not approved for colonization (e.g. nares, urine, etc). Maximum 28 days supply.LU Authorization Period: 1 year.MEFLOQUINE HCL0188250mgTabLariamHLR2007-06-06Apo-MefloquineAPX2007-06-06MOXIFLOXACIN HYDROCHLORIDE0189400mgTab5.7347AveloxBAY5.73472001-06-07For the treatment of patients with:CAP with co-morbidity: Community acquired pneumonia with co-morbid illnesses or failure to first-line therapy.LU Authorization Period: 1 year.COPD with risk: Acute bacterial exacerbation of chronic obstructive pulmonary disease (COPD) with risk factors*; bronchiectasis.*Risk factors include: poor pulmonary lung function (FEV1 below 50% predicted level), age over 65 years, co-morbid medical illness (congestive heart failure, diabetes, chronic renal failure, chronic liver disease), chronic corticosteroid use, malnutrition, prolonged duration of disease or 4 or more exacerbations per year.LU Authorization Period: 1 year.Step-Down: Step-down therapy after parenteral therapy or hospital / emergency department discharge.LU Authorization Period: 1 year.Exceptional cases of allergy or intolerance to all other appropriate therapies.LU Authorization Period: 1 year.NORFLOXACIN0190400mgTab1.08982.1796NoroxinMSD1996-10-01Apo-NorfloxAPX1.08982.17961999-04-15Novo-NorfloxacinNOP1.08982.17961999-04-15PMS-NorfloxacinPMS1.08982.17962003-04-16Co NorfloxacinCOB1.08982.17962006-09-06OFLOXACIN0191200mgTab1.30412.6082FloxinJNO1996-10-01Apo-OfloxAPX1.30412.60821998-12-31Novo-OfloxacinNOP1.30412.60822004-04-060192300mgTab1.21612.4322FloxinJNO1996-10-01Apo-OfloxAPX1.21612.43221998-12-31Novo-OfloxacinNOP1.21612.43222004-04-060193400mgTab1.21612.4322FloxinJNO1996-10-01Apo-OfloxAPX1.21612.43221998-12-31Novo-OfloxacinNOP1.21612.43222004-04-06For the treatment of patients with:SST/BJ (Gram negative bacteria): Skin/soft tissue and bone/joint infection due to gram negative bacteria; severe diabetic foot infection..LU Authorization Period: 1 year.GU Tract: Urinary tract infection / prostatitis / epididymitis; sexually transmitted disease.LU Authorization Period: 1 year.COPD with risk: Acute bacterial exacerbation of chronic obstructive pulmonary disease (COPD) with risk factors*; bronchiectasis.*Risk factors include: poor pulmonary lung function (FEV1 below 50% predicted level), age over 65 years, co-morbid medical illness (congestive heart failure, diabetes, chronic renal failure, chronic liver disease), chronic corticosteroid use, malnutrition, prolonged duration of disease or 4 or more exacerbations per year.LU Authorization Period: 1 year.GI: Traveller's diarrhea; enteric fever syndromes.LU Authorization Period: 1 year.Step-Down: Step-down therapy after parenteral therapy or hospital / emergency department discharge.LU Authorization Period: 1 year.Exceptional cases of allergy or intolerance to all other appropriate therapies.LU Authorization Period: 1 year.SULFAMETHOXAZOLE & TRIMETHOPRIMAvoid using sulfamethoxazole/trimethoprim during the last 6 weeks of pregnancy.019440mg & 8mg/mLO/L.0198.1980SeptraBWE1996-10-01Bactrim Sugar FreeHLR1996-10-01Novo-TrimelNOP.0198.19801996-10-010195400mg & 80mgTab.0482.1928SeptraBWE1996-10-01BactrimHLR1996-10-01Apo-SulfatrimAPX.0482.19281996-10-01Novo-TrimelNOP.0482.19281996-10-01Nu-CotrimoxNXP.0482.19281996-10-010196800mg & 160mgTab.1221.2442Septra DSBWE1996-10-01Bactrim-DSHLR1996-10-01Apo-Sulfatrim-DSAPX.1221.24421996-10-01Novo-Trimel DSNOP.1221.24421996-10-01Nu-CotrimoxNXP.1221.24421996-10-01TRIMETHOPRIM0197100mgTab.2566.5132ProloprimBWE1996-10-01Apo-TrimethoprimAPX.2566.51322001-06-070198200mgTab.5273.5273ProloprimBWE1996-10-01Apo-TrimethoprimAPX.5273.52732001-06-07ANTINEOPLASTIC AGENTSALTRETAMINE019950mgCap3.3600HexalenLIL3.36001996-10-01ANASTROZOLE02001mgTab4.9500ArimidexAZC4.95001996-12-19For the treatment of metastatic breast cancer in hormone receptor positive post-menopausal women.LU Authorization Period: Indefinite.As an alternative to tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer.LU Authorization Period: Indefinite.BICALUTAMIDE020150mgTab3.2200CasodexAZC6.44001996-12-19Novo-BicalutamideNOP3.22002006-04-04Co BicalutamideCOB3.22002006-04-04PMS-BicalutamidePMS3.22002006-04-04Sandoz BicalutamideSDZ3.22002006-04-04Ratio-BicalutamideRPH3.22002006-06-14Apo-BicalutamideAPX3.22002008-01-15Gen-BicalutamideGEN3.22002008-03-25BUSERELIN ACETATE02026.3mgImplant Kit724.6050Suprefact DepotSAV724.60501997-04-1002039.45mgImplant Kit1070.6850Suprefact DepotSAV1070.68502000-11-3002041mg/mLInj Sol-5.5mL Pk58.6900SuprefactSAV58.69001999-01-0802051mg/mLNas Sp-10mL Pk74.8800SuprefactSAV74.88001999-01-08BUSULFAN02062mgTab1.4376MyleranGSK1.43761996-10-01CAPECITABINE0207150mgTab1.8300XelodaHLR1.83002001-06-070208500mgTab6.1000XelodaHLR6.10002001-06-07For the first-line treatment of patients with metastatic colorectal cancer in whom combination chemotherapy is not recommended.Not to be used in patients who have failed 5-flurouracil.LU Authorization Period: Indefinite.For the treatment of metastatic breast cancer in combination with docetaxel in women who experience disease progression on or after an anthracycline.LU Authorization Period: Indefinite.For adjuvant treatment of stage 3 or high risk stage 2* colon cancer in patients who have completed surgery (within three months), who would normally be candidates for adjuvant chemotherapy with 5FU/LV. *high risk stage 2 colon cancer is defined as one of the following: - obstruction, - perforation, - poorly differentiated adenocarcinoma, - inadequate lymph node sampling, - T4 tumour. LU Authorization Period: 6 Months.As part of the CAPOX regimen for the first-line and second-line treatment of metastatic colorectal cancerLU Authorization Period: Indefinite.CHLORAMBUCIL02092mgTab1.3548LeukeranGSK1.35481996-10-01CLADRIBINE02101mg/mLInj55.1720LeustatinJNO55.17201996-10-01For hairy cell leukemia, as a single 7-day treatment course.LU Authorization Period: 1 year.CYCLOPHOSPHAMIDE0211200mgInj Pd-Vial Pk5.7630ProcytoxBAX5.76302005-05-2502121000mgInj Pd-Vial Pk13.4436ProcytoxBAX13.44362005-05-25021325mgTab.3520CytoxanBQU.37941996-10-01ProcytoxBAX.35202005-05-25021450mgTab.4740CytoxanBQU.51091996-10-01ProcytoxBAX.47402005-05-25CYPROTERONE ACETATE021550mgTab1.4085AndrocurBAY1.40851996-10-01Gen-CyproteroneGEN1.40851998-12-31Apo-CyproteroneAPX1.40852004-07-20CYTARABINE0216100mgInj Pd-Vial Pk10.0300CytosarPFI10.03001996-10-01DAUNORUBICIN0217Inj Pd-20mg Pk85.8500CerubidineERF85.85001996-10-01ESTRAMUSTINE PHOSPHATE DISODIUM0218140mgCap3.0070EmcytPFI3.00702006-10-23ETOPOSIDE021950mgCap34.0395VepesidBQU34.03951996-10-01EXEMESTANE022025mgTab4.9500AromasinPFI4.95002002-07-29For the hormonal treatment of metastatic breast cancer in hormone receptor positive post-menopausal women who have disease progression following tamoxifen therapy.LU Authorization Period: Indefinite.For the sequential treatment of postmenopausal women with estrogen receptor-positive early breast cancer who have received 2-3 years of initial adjuvant tamoxifen therapy. LU Authorization Period: Treatment period required to complete a total of 5 years of adjuvant therapy. FLUDARABINE PHOSPHATE022110mgTab38.9080FludaraBAY38.90802004-04-06For second line therapy of patients with chronic lymphocytic leukemia (CLL) who have failed or are intolerant to chlorambucil.LU Authorization Period: Indefinite.FLUTAMIDE0222250mgTab1.3530EuflexSCH1.35301996-10-01Novo-FlutamideNOP1.35301998-12-31PMS-FlutamidePMS1.35301998-12-31Apo-FlutamideAPX1.35301999-04-15GOSERELIN ACETATE02233.6mgDepot Inj381.7500ZoladexAZC381.75001996-10-01022410.8mgDepot Inj1087.9800Zoladex LAAZC1087.98001996-12-19HYDROXYUREA0225500mgCap1.0203HydreaBQU1.02031996-10-01Gen-HydroxyureaGEN1.02032002-07-29Apo-HydroxyureaAPX1.02032004-04-06IMATINIB MESYLATE0226100mgTab27.1062These products must be prescribed based on the following criteria: 1) For treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase. The initial dose is 400 mg/day. The dose may be increased up to a maximum of 800 mg/day in patients who do not have an adequate hematologic response at 3 months or cytogenetic response at 1 year; or if there has been loss of a previously achieved hematologic and/or cytogenetic response. 2) For treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in blast crisis or accelerated phase. The initial dose is 600 mg/day. The dose may be increased to a maximum of 800 mg/day in patients who do not have an adequate hematologic response at 3 months or cytogenetic response at 1 year; or loss of a previously achieved hematologic and/or cytogenetic response.GleevecNOV27.10622007-01-020227400mgTab108.4247These products must be prescribed based on the following criteria: 1) For treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase. The initial dose is 400 mg/day. The dose may be increased up to a maximum of 800 mg/day in patients who do not have an adequate hematologic response at 3 months or cytogenetic response at 1 year; or if there has been loss of a previously achieved hematologic and/or cytogenetic response. 2) For treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in blast crisis or accelerated phase. The initial dose is 600 mg/day. The dose may be increased to a maximum of 800 mg/day in patients who do not have an adequate hematologic response at 3 months or cytogenetic response at 1 year; or loss of a previously achieved hematologic and/or cytogenetic response.GleevecNOV108.42472007-01-02INTERFERON ALFA-2B022815mu/mL18mu MD Pen Kit210.0600Intron ASCH210.06002000-07-17022925mu/mL30mu MD Pen Kit350.1000Intron ASCH350.10002000-07-17023050mu/mL60mu MD Pen Kit700.1900Intron ASCH700.19002000-07-17For hairy cell leukemia.LU Authorization Period: Indefinite.For Kaposi's Sarcoma.LU Authorization Period: Indefinite.LETROZOLE02312.5mgTab5.5120FemaraNOV5.51201998-12-31For the treatment of metastatic breast cancer in hormone receptor positive post-menopausal women.LU Authorization Period: Indefinite.For the treatment of hormone receptor positive early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy.LU Authorization Period: 5 years.As an alternative to tamoxifen for the adjuvant treatment of post- menopausal women with hormone receptor positive early breast cancer for a maximum of five years.LU Authorization Period: 5 years.LEUPROLIDE ACETATE02323.75mgInj-Kit335.0600Lupron Depot PDSABB335.06001996-10-0102337.5mgInj-Kit387.9700Lupron Depot PDSABB387.97001996-10-01023411.25mgInj-Kit998.2700Lupron Depot PDSABB998.27002000-07-17023522.5mgInj-Kit1071.0000Lupron Depot PDSABB1071.00001997-08-28023630mgInj-Kit1428.0000Lupron Depot PDSABB1428.00002000-04-1702377.5mgPd Susp Inj-Pref Syr Kit343.5800EligardSAV343.58002004-07-20023822.5mgPd Susp Inj-Pref Syr Kit891.0000EligardSAV891.00002004-07-20023930mgPd Susp Inj-Pref Syr Kit1285.2000EligardSAV1285.20002005-05-25024045mgPd Susp Inj-Pref Syr Kit1450.0000EligardSAV1450.00002006-06-15LOMUSTINE (CCNU)024110mgCap6.1465CeeNUBQU6.14651996-10-01024240mgCap10.5805CeeNUBQU10.58051996-10-010243100mgCap17.4685CeeNUBQU17.46851996-10-01MEGESTROL ACETATE024440mgTab1.0073MegaceBQU1996-10-01Apo-MegestrolAPX1.00731996-10-010245160mgTab4.2630MegaceBQU5.85471996-10-01Apo-MegestrolAPX4.26301996-10-01MELPHALAN02462mgTab1.5672AlkeranGSK1.56721996-10-01MERCAPTOPURINE024750mgTab3.6680Decrease dose of mercaptopurine to 25-33% of initial dose if allopurinol used concomitantly.PurinetholNOP3.66801996-10-01METHOTREXATE024820mg/2mLInj Sol-2mL Pk12.5000Methotrexate SodiumMAY12.50002002-04-04024950mg/2mLInj Sol-2mL Pk12.4800MethotrexateWAY1998-03-17MethotrexateMAY12.48002005-10-0602502.5mgTab.6325MethotrexateWAY.63251997-02-04Apo-MethotrexateAPX.63252001-10-11Ratio-Methotrexate SodiumRPH.63252002-07-29NILUTAMIDE025150mgTab1.9679AnandronSAV1.96791999-01-06PROCARBAZINE HCL025250mgCap.4079Procarbazine inhibits monoamine oxidase. Avoid alcohol and foods with high tyramine content (e.g. aged cheese, red wine, yogurt, etc.)MatulaneSIG.40791996-10-01STREPTOZOCIN0253Inj Pd-1g Pk38.4500ZanosarPFI38.45001996-10-01TAMOXIFEN CITRATE025410mgTab.1750Apo-TamoxAPX.17501996-10-01Novo-TamoxifenNOP.17501996-10-01TamofenSAV.19301996-10-01NolvadexAZC1996-10-01Gen-TamoxifenGEN.17501996-10-01025520mgTab.3500Apo-TamoxAPX.35001996-10-01Novo-TamoxifenNOP.35001996-10-01TamofenSAV.38591996-10-01Nolvadex DAZC.36001996-10-01Gen-TamoxifenGEN.35001996-10-01TEMOZOLOMIDE02565mgCap7.3440TemodalSCH7.34402000-07-17025720mgCap29.3756TemodalSCH29.37562000-07-170258100mgCap146.8780TemodalSCH146.87802000-07-170259250mgCap367.1847TemodalSCH367.18472000-07-17For patients with recurrent or progressive glioblastoma multiforme or anaplastic astrocytoma..LU Authorization Period: Indefinite.THIOGUANINE026040mgTab4.1888LanvisGSK4.18881996-10-01TRIPTORELIN PAMOATE02613.75mg/VialInj Pd with Sterile Water-Vial Pk291.0000Trelstar (1 Month)PAL291.00002007-01-02026211.25mg/VialInj Pd with Sterile Water-Vial Pk891.0000Trelstar LA (3 Month)PAL891.00002007-01-0202633.75mg/VialInj Pd-Vial Pk291.0000Trelstar (1 Month)PAL291.00002007-01-02026411.25mg/VialInj Pd-Vial Pk891.0000Trelstar LA (3 Month)PAL891.00002007-01-02VINCRISTINE SULFATE02651mg/mLInj Sol7.1300OncovinLIL1996-10-01Vincristine SulfateNOP7.13001996-10-01AUTONOMIC AGENTSPARASYMPATHOMIMETIC (CHOLINERGIC) AGENTSBETHANECHOL CHLORIDE026610mgTab.2654DuvoidPAL.26541996-10-01026725mgTab.4300DuvoidPAL.43001996-10-01026850mgTab.5664DuvoidPAL.56641996-10-01CARBACHOL02692mgTab.3727CarbacholGLA.37271996-10-01DONEPEZIL HCL02705mgTab4.7771AriceptPFI4.77711999-06-01027110mgTab4.7771AriceptPFI4.77711999-06-01Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed. Network note: Maximum duration 3 months.LU Authorization Period: 1 year.Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.LU Authorization Period: 1 year.GALANTAMINE HYDROBROMIDE02728mgER Cap4.8690Reminyl ERJNO4.86902006-01-12027316mgER Cap4.8690Reminyl ERJNO4.86902006-01-12027424mgER Cap4.8690Reminyl ERJNO4.86902006-01-12Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed. Network note: Maximum duration 3 months.LU Authorization Period: 1 year.Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.LU Authorization Period: 1 year.NEOSTIGMINE BROMIDE027515mgTab.4370ProstigminVAL.43701996-10-01PYRIDOSTIGMINE BROMIDE0276180mgLA Tab.9397MestinonVAL.93971996-10-01027760mgTab.4295MestinonVAL.42951996-10-01RIVASTIGMINE02781.5mgCap2.6059ExelonNOV2.60592001-03-0702793mgCap2.6059ExelonNOV2.60592001-03-0702804.5mgCap2.6059ExelonNOV2.60592001-03-0702816mgCap2.6059ExelonNOV2.60592001-03-07Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed. Network note: Maximum duration 3 months.LU Authorization Period: 1 year.Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.LU Authorization Period: 1 year.PARASYMPATHOLYTIC (CHOLINERGIC BLOCKING) AGENTSAnticholinergic agents should be used with extreme caution in the elderly due to age- related central nervous system adverse effects (e.g., confusion, paranoia, hallucinations). Avoid in patients with dementia as drug-induced memory impairment is common. (This does not apply to ipratropium bromide).BENZTROPINE MESYLATE02822mgTab.0450CogentinMSD1996-10-01Apo-BenztropineAPX.04501996-10-01ETHOPROPAZINE HCL028350mgTab.2035ParsitanERF.20351996-10-01FLAVOXATE HCL0284200mgTabUrispasPAL1996-10-01Apo-FlavoxateAPX2002-07-29PMS-FlavoxatePMS2003-01-30IPRATROPIUM BROMIDE0285250mcg/mLInh Sol-20mL Pk8.7850AtroventBOE1996-10-01Ratio-IpratropiumRPH8.78501996-10-01Apo-Ipravent Inhalation SolutionAPX8.78502000-11-30Novo-IpramideNOP8.78501999-04-15PMS-IpratropiumPMS8.78501999-04-15Gen-IpratropiumGEN8.78502000-04-17For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.Patients who have a tracheostomy;LU Authorization Period: Indefinite.Patients with cystic fibrosis in whom nebulizer therapy is indicated;LU Authorization Period: Indefinite.Patients with severe mental or physical disabilities;LU Authorization Period: Indefinite.Patients who have previously used nebulizer therapy within the last 12 month period.LU Authorization Period: Indefinite.0286125mcg/mLInh Sol-2mL UDV Pk.6590Atrovent UDVBOE1996-10-01Ratio-Ipratropium UDVRPH.65901998-12-31PMS-IpratropiumPMS.65901999-04-150287250mcg/mLInh Sol-2mL UDV Pk1.3180Atrovent UDVBOE1996-10-01Ratio-Ipratropium UDVRPH1.31801996-12-19Gen-IpratropiumGEN1.31801999-09-15PMS-IpratropiumPMS1.31801999-04-15For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;LU Authorization Period: Indefinite.Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.LU Authorization Period: Indefinite.Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;LU Authorization Period: Indefinite.Patients who have previously used nebulizer therapy within the last 12 month period.LU Authorization Period: Indefinite.028820mcg/Metered DoseInh-200 Dose Pk18.3400Atrovent HFABOE18.34002004-11-04IPRATROPIUM BROMIDE/SALBUTAMOL0289500mcg/2.5mg/2.5mLInh Sol-2.5mL Pk.7340Combivent UDVBOE1.50751998-12-31Ratio-IPRA SAL UDVRPH.73402003-01-30Gen-Combo SterinebsGEN.73402006-01-24For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.Patients who have a tracheostomy;LU Authorization Period: Indefinite.Patients with cystic fibrosis in whom nebulizer therapy is indicated;LU Authorization Period: Indefinite.Patients with severe mental or physical disabilities;LU Authorization Period: Indefinite.Patients who have previously used nebulizer therapy within the last 12 month period.LU Authorization Period: Indefinite.OXYBUTYNIN CHLORIDE02901mg/mLO/L.0444DitropanJNO1996-10-01PMS-OxybutyninPMS.04441998-12-3102915mgTab.1973DitropanPGP1996-10-01Nu-OxybutynNXP.19731996-10-01Apo-OxybutyninAPX.19731996-10-01Novo-OxybutyninNOP.19731998-12-31Gen-OxybutyninGEN.19731998-12-31PMS-OxybutyninPMS.19732000-07-17PROCYCLIDINE HCL02920.5mg/mLO/L.0307KemadrinBWE.03071996-10-0102932.5mgTab.0555PMS-ProcyclidinePMS.05551996-10-0102945mgTab.0255KemadrinBWE1996-10-01PMS-ProcyclidinePMS.02551996-10-01TIOTROPIUM BROMIDE MONOHYDRATE029518mcgCap2.1000SpirivaBOE2.10002003-09-04TRIHEXYPHENIDYL HCL02962mgTab.0369ArtaneLED1996-10-01Apo-TrihexAPX.03691996-10-0102975mgTab.0668ArtaneLED1996-10-01Apo-TrihexAPX.06681996-10-01TRIMEBUTINE MALEATE0298100mgTabModulonAXC2008-01-15Apo-TrimebutineAPX2008-01-150299200mgTabModulonAXC2008-01-15Apo-TrimebutineAPX2008-01-15SYMPATHOMIMETIC (ADRENERGIC) AGENTSSolutions for use in nebulizers are more expensive than metered dose inhalers (MDI) and turbuhalers, and for most patients, there is no significant benefit. The only indication for this mode of administration is for selected patient groups, such as those noted in the Limited Use clinical criteria for solutions for use in nebulizers, who are unable to use other formulations. Even children who are unable to coordinate actuation of a MDI and inhalation can usually use a spacer or turbuhaler. Special fittings are available for patients with severe arthritis who have difficulty using a standard MDI.BUDESONIDE & FORMOTEROL FUMARATE DIHYDRATE0300100mcg/6mcgPd Inh-120 Dose Pk60.0000Symbicort 100 TurbuhalerAZC60.00002003-01-300301200mcg/6mcgPd Inh-120 Dose Pk78.0000Symbicort 200 TurbuhalerAZC78.00002003-01-30For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.LU Authorization Period: Indefinite.EPINEPHRINE HCL030230mg/30mLInj Sol-30mL Pk16.5000AdrenalinERF16.50001996-10-01FORMOTEROL FUMARATE030312mcg/CapInh Pd-Device Pk46.9500ForadilNOV46.95001998-12-31For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.This drug is not for relief of acute symptoms.LU Authorization Period: Indefinite.FORMOTEROL FUMARATE DIHYDRATE03046mcg/Metered DosePd Inh-60 Dose Pk32.7000Oxeze TurbuhalerAZC32.70002001-03-07030512mcg/Metered DosePd Inh-60 Dose Pk43.5500Oxeze TurbuhalerAZC43.55001999-04-15For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.This drug is not for relief of acute symptoms.LU Authorization Period: Indefinite.ISOPROTERENOL HCL03060.5%Inh Sol-10mL Pk8.4700IsuprelSAO8.47001996-10-01For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.Children aged 6 years or less;LU Authorization Period: Indefinite.Patients who have a tracheostomy;LU Authorization Period: Indefinite.Patients with cystic fibrosis in whom nebulizer therapy is indicated;LU Authorization Period: Indefinite.Patients with severe mental or physical disabilities;LU Authorization Period: Indefinite.Patients who have previously used nebulizer therapy within the last 12 month period.LU Authorization Period: Indefinite.ORCIPRENALINE SULFATE03072mg/mLO/L.0302AlupentBOE1996-10-01Tanta OrciprenalineTAN.03021997-04-10Apo-OrciprenalineAPX.03022001-03-07PSEUDOEPHEDRINE HCL03086mg/mLO/LSudafedBWE1996-10-01RobidrineWHB1996-10-01030960mgTabSudafedBWE1996-10-01RobidrineWHB1996-10-01SALBUTAMOL03101mg/mLInh Sol- 2.5mL Pk.4828Gen-Salbutamol Sterinebs P.F.GEN.48281996-10-01Ratio-Salbutamol Respirator Sol P.F.RPH.48281996-10-01PMS-SalbutamolPMS.48281997-04-10Ventolin Nebules P.F.GSK1.03351998-10-21For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;LU Authorization Period: Indefinite.Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.LU Authorization Period: Indefinite.Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;LU Authorization Period: Indefinite.Patients who have previously used nebulizer therapy within the last 12 month period.LU Authorization Period: Indefinite.03112mg/mLInh Sol- 2.5mL Pk.9173Gen-SalbutamolGEN.91731997-04-10PMS-SalbutamolPMS.91731997-04-10Ventolin Nebules P.F.GSK1.96302006-06-15Ratio-SalbutamolRPH.91732001-03-07For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;LU Authorization Period: Indefinite.Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.LU Authorization Period: Indefinite.Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;LU Authorization Period: Indefinite.Patients who have previously used nebulizer therapy within the last 12 month period.LU Authorization Period: Indefinite.03125mg/mLInh Sol-10mL Pk4.6850Ratio-Salbutamol Respirator SolRPH4.68501996-10-01PMS-Salbutamol Respirator SolutionPMS4.68501996-10-01Sandoz SalbutamolSDZ4.68501996-10-01VentolinGSK10.03001998-04-03Gen-SalbutamolGEN4.68501999-04-15For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.Patients who have a tracheostomy;LU Authorization Period: Indefinite.Patients with cystic fibrosis in whom nebulizer therapy is indicated;LU Authorization Period: Indefinite.Patients with severe mental or physical disabilities;LU Authorization Period: Indefinite.Patients who have previously used nebulizer therapy within the last 12 month period.LU Authorization Period: Indefinite.0313100mcg/Metered DoseInh-200 dose Pk7.7300Apo-SalventAPX1996-10-01Ratio-Salbutamol InhalerRPH1996-10-01Novo-SalmolNOP1996-10-01VentolinGLW1997-07-12Airomir HFAMMH1998-12-31Ratio-Salbutamol HFARPH7.73002002-07-29Apo-Salvent CFC FreeAPX7.73002003-01-0103140.4mg/mLO/L.0476PMS-SalbutamolPMS.04762004-12-21VentolinGSK.07111998-03-1703152mgTab.1274VentolinGLA1996-10-01Apo-SalventAPX.12741996-10-0103164mgTab.2134VentolinGLA1996-10-01Apo-SalventAPX.21341996-10-01SALMETEROL XINAFOATE031750mcg/BlisterDiskhaler-60 Disk Pk56.1000SereVent Diskhaler DisksGSK56.10001997-07-12031850mcgPd Inh-60 Dose Pk56.1000SereVent DiskusGSK56.10001998-12-31For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.This drug is not for relief of acute symptoms.LU Authorization Period: Indefinite.For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic.LU Authorization Period: Indefinite.SALMETEROL XINAFOATE & FLUTICASONE PROPIONATE031925/125mcg/Metered DoseInh-120 Dose Pk95.9900Advair 125GSK95.99002003-01-30032025/250mcg/Metered DoseInh-120 Dose Pk136.2700Advair 250GSK136.27002003-01-30032150/100mcgInh-60 Dose Pk80.1900Advair DiskusGSK80.19002001-10-11032250/250mcgInh-60 Dose Pk95.9900Advair DiskusGSK95.99002000-07-17032350/500mcgInh-60 Dose Pk136.2700Advair DiskusGSK136.27002000-07-17For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.LU Authorization Period: Indefinite.TERBUTALINE SULFATE03240.5mg/DoseInh-200 Dose Pk14.7000Bricanyl TurbuhalerAZC14.70001996-10-01SYMPATHOLYTIC (ADRENERGIC BLOCKING) AGENTSErgotamine is the drug of choice in the treatment of acute attacks of migraine. It may also alleviate or prevent acute attacks of cluster headache in some patients. The addition of caffeine or pentobarbital have not been proven to result in greater efficacy.ERGOTAMINE TARTRATE & CAFFEINE03251mg & 100mgTab.7902CafergotNOV.79021996-10-01METHYSERGIDE BIMALEATE03262mgTab.9616Fibrosis (retroperitoneal and pleuropulmonary) occurs rarely with prolonged therapy. Daily dose should not exceed 8mg, and duration of therapy should not exceed six months in a single course of therapy. It should be reserved for migraine headache prophylaxis not responsive to other prophylactic agents (e.g., beta blockers).SansertNOV.96161996-10-01SKELETAL MUSCLE RELAXANTSMuscle relaxants, other than baclofen and dantrolene sodium, are not indicated for spasticity due to cerebral palsy, multiple sclerosis, spinal cord injury, etc.BACLOFEN032710mgTab.2311LioresalNOV.63791996-10-01PMS-BaclofenPMS.23111996-10-01Gen-BaclofenGEN.23111996-10-01Nu-BacloNXP.23111996-10-01Apo-BaclofenAPX.23111996-10-01Ratio-BaclofenRPH.23111999-04-15032820mgTab.4498Lioresal DSNOV1.24151996-10-01PMS-BaclofenPMS.44981996-10-01Gen-BaclofenGEN.44981996-10-01Nu-BacloNXP.44981996-10-01Apo-BaclofenAPX.44981996-10-01Ratio-BaclofenRPH.44981999-04-15CYCLOBENZAPRINE HCL032910mgTabFlexerilFRS1996-10-01Novo-CycloprineNOP1996-10-01Nu-CyclobenzaprineNXP1996-10-01Apo-CyclobenzaprineAPX1996-10-01PMS-CyclobenzaprinePMS1996-12-19Gen-CycloprineGEN1998-12-31Ratio-CyclobenzaprineRPH1999-09-15DANTROLENE SODIUM033025mgCap.3780DantriumJHP.37801996-10-010331100mgCap.7684DantriumJHP.76841996-10-01ORPHENADRINE CITRATE033260mg/2mLInj Sol-2mL PkNorflexMMH1996-10-01OrphenadrineCYI1998-12-31TIZANIDINE HCL03334mgTabZanaflexELA2007-06-06Apo-TizanidineAPX2007-06-06Gen-TizanidineGEN2007-06-06BLOOD FORMATION AND COAGULATIONANTIANEMIA DRUGSFERROUS FUMARATE0334300mgCap.1234PalaferGSK.20131996-10-01Euro-FerEUR.12342006-07-19033560mg/mLO/L.0857PalaferGSK.08571996-10-01FERROUS GLUCONATE0336300mgTab.0212Novo-FerroglucNOP.02121996-10-01Ferrous GluconateRPR1996-10-01Apo-Ferrous GluconateAPX.02121996-10-01FERROUS SULFATE033775mg/mLO/L.2436Fer-In-SolMJS.24361997-01-03COAGULANTS AND ANTI-COAGULANTSDALTEPARIN SODIUM03382500IU/0.2mLInj Pref Syr4.9400FragminPFI4.94001996-10-0103395000IU/0.2mLInj Pref Syr9.8800FragminPFI9.88001997-04-10034010000IU/0.4mLInj Pref Syr19.7600FragminPFI19.76002001-06-07034112500IU/0.5mLInj Pref Syr24.7000FragminPFI24.70002001-06-07034215000IU/0.6mLInj Pref Syr29.6400FragminPFI29.64002001-06-07034318000IU/0.72mLInj Pref Syr35.5680FragminPFI35.56802001-06-07034410000IU/mLInj Sol-1mL Pk15.6000FragminPFI15.60001996-10-01034525000IU/mLMultidose 3.8mL Pk148.2000FragminPFI148.20001998-12-31For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;LU Authorization Period: 1 year.For DVT in pregnant or lactating females;LU Authorization Period: 1 year.For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;LU Authorization Period: 1 year.For DVT in patients who have failed treatment with warfarin.LU Authorization Period: 1 year.ENOXAPARIN0346100mg/mLInj Sol-3mLVial Pk61.5000LovenoxSAV61.50002003-01-30034730mg/0.3mLPref Syr-0.3mL Pk6.1900LovenoxSAV6.19002003-01-30034840mg/0.4mLPref Syr-0.4mL Pk8.2000LovenoxSAV8.20002003-01-30034960mg/0.6mLPref Syr-0.6mL Pk12.3000LovenoxSAV12.30002003-01-30035080mg/0.8mLPref Syr-0.8mL Pk16.4000LovenoxSAV16.40002003-01-300351120mg/0.8mLPref Syr-0.8mL Pk24.6000Lovenox HPSAV24.60002005-02-220352100mg/mLPref Syr-1mL Pk20.5000LovenoxSAV20.50002003-01-300353150mg/mLPref Syr-1mL Pk30.7500Lovenox HPSAV30.75002005-02-22For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;LU Authorization Period: 1 year.For DVT in pregnant or lactating females;LU Authorization Period: 1 year.For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;LU Authorization Period: 1 year.For DVT in patients who have failed treatment with warfarin.LU Authorization Period: 1 year.For the acute treatment of pulmonary embolism, maximum of three weeks.LU Authorization Period: 1 year.FONDAPARINUX SODIUM03542.5mgInj-0.5mL Pk15.4320ArixtraGSK15.43202004-04-06For the post-operative prophylaxis of venous thromboembolic events in patients undergoing orthopedic surgery of the lower limbs such as hip fracture, hip replacement or knee surgery.Limited to 9 days of reimbursement.LU Authorization Period: 1 year.HEPARIN SODIUM035510000USP U/10mLInj Sol-10mL Pk3.5000HepaleanORG3.50001996-10-01035650000USP U/5mLInj Sol-5mL Pk5.8900HepaleanORG5.89001996-10-01NADROPARIN CALCIUM03579500IU/mLPref Syr-0.3mL Pk9.1290FraxiparineGSK9.12901999-04-1503589500IU/mLPref Syr-0.4mL Pk9.1290FraxiparineGSK9.12901999-04-1503599500IU/mLPref Syr-0.6mL Pk9.1290FraxiparineGSK9.12901999-04-15036019000IU/mLPref Syr-0.6mL Pk18.2580Fraxiparine ForteGSK18.25802000-01-1703619500IU/mLPref Syr-0.8mL Pk9.1290FraxiparineGSK9.12901999-04-15036219000IU/mLPref Syr-0.8mL Pk18.2580Fraxiparine ForteGSK18.25802000-01-1703639500IU/mLPref Syr-1.0mL Pk9.1290FraxiparineGSK9.12901999-04-15036419000IU/mLPref Syr-1.0mL Pk18.2580Fraxiparine ForteGSK18.25802000-01-17For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;LU Authorization Period: 1 year.For DVT in pregnant or lactating females;LU Authorization Period: 1 year.For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;LU Authorization Period: 1 year.For DVT in patients who have failed treatment with warfarin.LU Authorization Period: 1 year.RIVAROXABAN036510mgTab9.9200Note: For the prevention of venous thromboembolic events in patients who have undergone elective total hip replacement (THR) or total knee replacement (TKR) surgery. NOTE: Limited to 14 days of reimbursementXareltoBAH9.92002009-06-23TINZAPARIN SODIUM036610000IU/mLInj - 2mL Pk32.0000InnohepLEO32.00001997-04-10036720000IU/mLInj - 2mL Pk65.0000InnohepLEO65.00001998-12-3103683500IU/0.35mLInj Pref Syr5.6450InnohepLEO5.64501998-12-3103694500IU/0.45mLInj Pref Syr7.2580InnohepLEO7.25801998-12-31037010000IU/0.5mLInj Pref Syr16.4800InnohepLEO16.48001998-12-31037114000IU/0.7mLInj Pref Syr23.0700InnohepLEO23.07001998-12-31037218000IU/0.9mLInj Pref Syr29.6600InnohepLEO29.66001998-12-31For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;LU Authorization Period: 1 year.For DVT in pregnant or lactating females;LU Authorization Period: 1 year.For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;LU Authorization Period: 1 year.For DVT in patients who have failed treatment with warfarin.LU Authorization Period: 1 year.For the acute treatment of pulmonary embolism, maximum of three weeks.LU Authorization Period: 1 year.WARFARINThe use of International Normalized Ratio (INR) instead of Prothrombin Time results to control warfarin dosing is strongly recommended. Prothrombin Time results can vary three-fold depending on the reagent used; INR corrects for this and substantially improves safety and efficacy of warfarin therapy.03731mgTab.1415CoumadinBQU.31201996-10-01Taro-WarfarinTAR.14152001-06-07Apo-WarfarinAPX.14152001-06-07Gen-WarfarinGEN.14152003-01-30Novo-WarfarinNOP.14152005-09-1603742mgTab.1496CoumadinBQU.32991996-10-01Taro-WarfarinTAR.14962001-06-07Apo-WarfarinAPX.14962001-06-07Gen-WarfarinGEN.14962003-01-30Novo-WarfarinNOP.14962005-09-1603752.5mgTab.1198CoumadinBQU.26411996-10-01Taro-WarfarinTAR.11982001-06-07Apo-WarfarinAPX.11982001-06-07Gen-WarfarinGEN.11982003-01-30Novo-WarfarinNOP.11982005-09-1603763mgTab.1855CoumadinBQU.40902001-06-07Taro-WarfarinTAR.18552002-04-04Apo-WarfarinAPX.18552003-01-30Novo-WarfarinNOP.18552005-09-16Gen-WarfarinGEN.19102007-03-0903774mgTab.1855CoumadinBQU.40901996-10-01Taro-WarfarinTAR.18552001-06-07Apo-WarfarinAPX.18552001-06-07Gen-WarfarinGEN.18552003-01-30Novo-WarfarinNOP.18552005-09-1603785mgTab.1200CoumadinBQU.26461996-10-01Taro-WarfarinTAR.12002001-06-07Apo-WarfarinAPX.12002001-06-07Gen-WarfarinGEN.12002003-01-30Novo-WarfarinNOP.12002005-09-1603796mgTabCoumadinBQU2008-06-27Taro-WarfarinTAR2008-12-03Gen-WarfarinGEN2008-06-27038010mgTab.2153CoumadinBQU.47481996-10-01Taro-WarfarinTAR.21532001-06-07Apo-WarfarinAPX.21532001-06-07Gen-WarfarinGEN.21532003-01-30HEMATOPOIETIC AGENTSDARBEPOETIN ALFA0381150mcg/0.3mLPref Syr-0.3mL Pk402.0000These products must be prescribed based on the following criteria: For the treatment of chemotherapy-induced anemia in patients with malignant cancer undergoing myelosuppressive chemotherapy with a hemoglobin count of less than 100g/L and MCV level between 75fL and 120fL. Note: Darbepoietin therapy should be re-assessed after 3 months of therapy and should not be continued for those patients who do not respond to therapy (i.e. Hgb level has not improved by at least 15g/L or transfusions were required after first 2 weeks of therapy) or who are no longer anemic. The following dosage regimens for Aranesp are recommended by the Committee to Evaluate Drugs : I. 200mcg q2weekly x 6 weeks, then increase to 300mcg q2weekly if inadequate response; OR II. 500mcg q3weekly x maximum duration of 3 cycles, then decrease to 300mcg q3weekly for maintenance; OR III. 150mcg qweeklyAranespAMG402.00002007-01-020382200mcg/0.4mLPref Syr-0.4mL Pk536.0000These products must be prescribed based on the following criteria: For the treatment of chemotherapy-induced anemia in patients with malignant cancer undergoing myelosuppressive chemotherapy with a hemoglobin count of less than 100g/L and MCV level between 75fL and 120fL. Note: Darbepoietin therapy should be re-assessed after 3 months of therapy and should not be continued for those patients who do not respond to therapy (i.e. Hgb level has not improved by at least 15g/L or transfusions were required after first 2 weeks of therapy) or who are no longer anemic. The following dosage regimens for Aranesp are recommended by the Committee to Evaluate Drugs : I. 200mcg q2weekly x 6 weeks, then increase to 300mcg q2weekly if inadequate response; OR II. 500mcg q3weekly x maximum duration of 3 cycles, then decrease to 300mcg q3weekly for maintenance; OR III. 150mcg qweeklyAranespAMG536.00002007-01-020383300mcg/0.6mLPref Syr-0.6mL Pk828.0000These products must be prescribed based on the following criteria: For the treatment of chemotherapy-induced anemia in patients with malignant cancer undergoing myelosuppressive chemotherapy with a hemoglobin count of less than 100g/L and MCV level between 75fL and 120fL. Note: Darbepoietin therapy should be re-assessed after 3 months of therapy and should not be continued for those patients who do not respond to therapy (i.e. Hgb level has not improved by at least 15g/L or transfusions were required after first 2 weeks of therapy) or who are no longer anemic. The following dosage regimens for Aranesp are recommended by the Committee to Evaluate Drugs : I. 200mcg q2weekly x 6 weeks, then increase to 300mcg q2weekly if inadequate response; OR II. 500mcg q3weekly x maximum duration of 3 cycles, then decrease to 300mcg q3weekly for maintenance; OR III. 150mcg qweeklyAranespAMG828.00002007-01-020384500mcg/1.0mLPref Syr-1.0mL Pk1380.0000These products must be prescribed based on the following criteria: For the treatment of chemotherapy-induced anemia in patients with malignant cancer undergoing myelosuppressive chemotherapy with a hemoglobin count of less than 100g/L and MCV level between 75fL and 120fL. Note: Darbepoietin therapy should be re-assessed after 3 months of therapy and should not be continued for those patients who do not respond to therapy (i.e. Hgb level has not improved by at least 15g/L or transfusions were required after first 2 weeks of therapy) or who are no longer anemic. The following dosage regimens for Aranesp are recommended by the Committee to Evaluate Drugs : I. 200mcg q2weekly x 6 weeks, then increase to 300mcg q2weekly if inadequate response; OR II. 500mcg q3weekly x maximum duration of 3 cycles, then decrease to 300mcg q3weekly for maintenance; OR III. 150mcg qweeklyAranespAMG1380.00002007-01-02EPOETIN ALFA038520,000IU/mLInj Sol - 1mL Vial Pk267.9000These products must be prescribed based on the following criteria: For the treatment of chemotherapy-induced anemia in patients with malignant cancer undergoing myelosuppressive chemotherapy with a hemoglobin count of less than 100g/L and MCV level between 75fL and 120fL. Note: Erythropoietin therapy should be re-assessed after 3 months of therapy and should not be continued for those patients who do not respond to therapy (i.e. Hgb level has not improved by at least 15g/L or transfusions were required after first 2 weeks of therapy) or who are no longer anemic. The following dosage regimens for Eprex are recommended by the Committee to Evaluate Drugs: I. 150 IU/kg subcutaneously 3 times a week for 4 weeks. If no response, the dose may be increased to 300 IU/kg subcutaneously 3 times a week; OR II. 40,000 IU once weekly. If no response after 4 weeks, the dose may be increased to 60,000 IU once weekly for 4 weeks.EprexJNO267.90002007-01-02038610,000IU/mLPref Syr - 1mL Pk142.5000These products must be prescribed based on the following criteria: For the treatment of chemotherapy-induced anemia in patients with malignant cancer undergoing myelosuppressive chemotherapy with a hemoglobin count of less than 100g/L and MCV level between 75fL and 120fL. Note: Erythropoietin therapy should be re-assessed after 3 months of therapy and should not be continued for those patients who do not respond to therapy (i.e. Hgb level has not improved by at least 15g/L or transfusions were required after first 2 weeks of therapy) or who are no longer anemic. The following dosage regimens for Eprex are recommended by the Committee to Evaluate Drugs: I. 150 IU/kg subcutaneously 3 times a week for 4 weeks. If no response, the dose may be increased to 300 IU/kg subcutaneously 3 times a week; OR II. 40,000 IU once weekly. If no response after 4 weeks, the dose may be increased to 60,000 IU once weekly for 4 weeks.EprexJNO142.50002007-01-02038740,000IU/mLPref Syr - 1mL Pk401.8500These products must be prescribed based on the following criteria: For the treatment of chemotherapy-induced anemia in patients with malignant cancer undergoing myelosuppressive chemotherapy with a hemoglobin count of less than 100g/L and MCV level between 75fL and 120fL. Note: Erythropoietin therapy should be re-assessed after 3 months of therapy and should not be continued for those patients who do not respond to therapy (i.e. Hgb level has not improved by at least 15g/L or transfusions were required after first 2 weeks of therapy) or who are no longer anemic. The following dosage regimens for Eprex are recommended by the Committee to Evaluate Drugs: I. 150 IU/kg subcutaneously 3 times a week for 4 weeks. If no response, the dose may be increased to 300 IU/kg subcutaneously 3 times a week; OR II. 40,000 IU once weekly. If no response after 4 weeks, the dose may be increased to 60,000 IU once weekly for 4 weeks.EprexJNO401.85002007-01-02038820,000IU/0.5mLPref Syr-0.5mL Pk267.9000For patients with malignant cancer undergoing myelosuppressive chemotherapy with hemoglobin count less than 100g/L and MCV level between 75fL and 120fL. Note: Erythropoietin therapy should be re-assessed after 3 months of therapy and should not be continued for those patients who do not respond to therapy (i.e. Hgb level has not improved by at least 15g/L or transfusions were required after first 2 weeks of therapy) or who are no longer anemic. EprexJNO267.90002009-03-02HEMORRHEOLOGIC AGENTSPENTOXIFYLLINE0389400mgSR Tab.3046Ratio-PentoxifyllineRPH.30461998-12-31TrentalSAV.77951999-01-07Apo-PentoxifyllineAPX.30461997-08-28Nu-PentoxifyllineNXP.30461999-04-15For the treatment of patients with critical limb ischemia (with arterial ulcers, gangrene and/or rest pain) and documented arterial vascular disease.Limited Use form must specify if arterial ulcers, gangrene and/or rest pain are present.LU Authorization Period: Indefinite.CARDIOVASCULAR DRUGSCARDIAC DRUGSACEBUTOLOL HCL0390100mgTab.1294.2588RhotralSAV.1294.25881996-10-01SectralSAV.3146.62921996-10-01MonitanWAY1996-10-01Apo-AcebutololAPX.1294.25881996-10-01Nu-AcebutololNXP.1294.25881998-12-31Novo-AcebutololNOP.1294.25881998-12-31Gen-AcebutololGEN.1294.25881999-04-15Gen-Acebutolol (Type S)GEN.1294.25882000-01-17Sandoz AcebutololSDZ.1294.25882005-01-250391200mgTab.1936.3872RhotralSAV.1936.38721996-10-01SectralSAV.4708.94161996-10-01MonitanWAY1996-10-01Apo-AcebutololAPX.1936.38721996-10-01Nu-AcebutololNXP.1936.38721998-12-31Novo-AcebutololNOP.1936.38721998-12-31Gen-AcebutololGEN.1936.38721999-04-15Gen-Acebutolol (Type S)GEN.1936.38722000-01-17Sandoz AcebutololSDZ.1936.38722005-01-250392400mgTab.3847.7694RhotralSAV.3847.76941996-10-01SectralSAV.98621.97241996-10-01MonitanWAY1996-10-01Apo-AcebutololAPX.3847.76941996-10-01Nu-AcebutololNXP.3847.76941998-12-31Novo-AcebutololNOP.3847.76941997-08-28Gen-AcebutololGEN.3847.76941999-04-15Gen-Acebutolol (Type S)GEN.3847.76942000-01-17Sandoz AcebutololSDZ.3847.76942005-01-25AMIODARONE HCL0393200mgTab1.0295The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.CordaroneWAY2.05891996-10-01Novo-AmiodaroneNOP1.02951999-09-15Ratio-AmiodaroneRPH1.02952000-01-17Gen-AmiodaroneGEN1.02952000-01-17PMS-AmiodaronePMS1.02952001-06-07Sandoz AmiodaroneSDZ1.02952002-07-29Apo-AmiodaroneAPX1.02952004-04-06AMLODIPINE03945mgTab.6656.6656NorvascPFI1.33121.33121996-10-01Novo-AmlodipineNOP.6656.66562009-09-30Ratio-AmlodipineRPH.6656.66562009-09-30Gen-AmlodipineGEN.6656.66562009-09-30Apo-AmlodipineAPX.6656.66562009-09-30Gd-AmlodipineGEM.6656.66562009-09-30PMS-AmlodipinePMS.6656.66562009-09-30Sandoz AmlodipineSDZ.6656.66562009-09-30Co AmlodipineCOB.6656.66562009-09-30Ran-AmlodipineRAN.6656.66562009-09-30Phl-AmlodipinePHE.6656.66562009-09-30039510mgTab.9880.9880NorvascPFI1.97601.97601996-10-01Novo-AmlodipineNOP.9880.98802009-09-30Ratio-AmlodipineRPH.9880.98802009-09-30Gen-AmlodipineGEN.9880.98802009-09-30Apo-AmlodipineAPX.9880.98802009-09-30Gd-AmlodipineGEM.9880.98802009-09-30PMS-AmlodipinePMS.9880.98802009-09-30Sandoz AmlodipineSDZ.9880.98802009-09-30Co AmlodipineCOB.9880.98802009-09-30Ran-AmlodipineRAN.9880.98802009-09-30Phl-AmlodipinePHE.9880.98802009-09-30ATENOLOL039650mgTab.2790.2790Apo-AtenolAPX.2790.27901996-10-01Nu-AtenolNXP.2790.27901996-10-01Novo-AtenolNOP.2790.27901996-10-01TenorminAZC.5746.57461996-10-01Gen-AtenololGEN.2790.27901996-10-01Ratio-AtenololRPH.2790.27901996-10-01Sandoz AtenololSDZ.2790.27902000-01-17PMS-AtenololPMS.2790.27901999-04-15Co-AtenololCOB.2790.27902004-10-14Ran-AtenololRAN.2790.27902006-03-010397100mgTab.4586.4586Apo-AtenolAPX.4586.45861996-10-01Nu-AtenolNXP.4586.45861996-10-01Novo-AtenolNOP.4586.45861996-10-01TenorminAZC.9446.94461996-10-01Gen-AtenololGEN.4586.45861996-10-01Ratio-AtenololRPH.4586.45861996-10-01Sandoz AtenololSDZ.4586.45862000-01-17PMS-AtenololPMS.4586.45861999-04-15Co-AtenololCOB.4586.45862004-10-14Ran-AtenololRAN.4586.45862006-03-01BISOPROLOL FUMARATE03985mgTab.1750MonocorBIO.39742001-06-07Sandoz BisoprololSDZ.17502003-09-04Apo-BisoprololAPX.17502004-11-16Novo-BisoprololNOP.17502005-08-19PMS-BisoprololPMS.17502008-02-12039910mgTab.2900MonocorCRY.58002001-06-07Sandoz BisoprololSDZ.29002003-09-04Apo-BisoprololAPX.29002004-11-16Novo-BisoprololNOP.29002005-08-19PMS-BisoprololPMS.29002008-02-12CARVEDILOL04003.125mgTab.63501.2700CoregGSK1997-04-10PMS-CarvedilolPMS.63501.27002004-04-06Apo-CarvedilolAPX.63501.27002004-04-06Ratio-CarvedilolRPH.63501.27002004-07-20Ran-CarvedilolRAN.63501.27002005-12-0604016.25mgTab.63501.2700CoregGSK1997-04-10PMS-CarvedilolPMS.63501.27002004-04-06Apo-CarvedilolAPX.63501.27002004-04-06Ratio-CarvedilolRPH.63501.27002004-07-20Ran-CarvedilolRAN.63501.27002005-12-06040212.5mgTab.63501.2700CoregGSK1997-04-10PMS-CarvedilolPMS.63501.27002004-04-06Apo-CarvedilolAPX.63501.27002004-04-06Ratio-CarvedilolRPH.63501.27002004-07-20Ran-CarvedilolRAN.63501.27002005-12-06040325mgTab.63501.2700CoregGSK1997-04-10PMS-CarvedilolPMS.63501.27002004-04-06Apo-CarvedilolAPX.63501.27002004-04-06Ratio-CarvedilolRPH.63501.27002004-07-20Ran-CarvedilolRAN.63501.27002005-12-06For patients with:a) NYHA Class II or III Congestive Heart Failure (CHF); and b) Currently being treated with an angiotension converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and c) An ejection fraction less than or equal to 35%; and d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.LU Authorization Period: Indefinite.DIGOXINDigoxin toxicity is common and serious: digoxin levels should be monitored in the elderly, after adding drugs that affect urea clearance including diuretics, particularly spironolactone; verapamil and quinidine also interact significantly with digoxin. Dose should be reduced in renal impairment and in elderly patients. Chronic therapy should be re-evaluated.04040.05mg/mLO/L.3561LanoxinVRO.35612002-04-0404050.0625mgTab.1089LanoxinVRO.21772002-04-04Apo-DigoxinAPX.10892006-08-2404060.125mgTab.1030LanoxinVRO.20602001-10-11Apo-DigoxinAPX.10302006-08-2404070.25mgTab.1030LanoxinVRO.20602001-10-11Apo-DigoxinAPX.10302006-08-24DILTIAZEM HCL0408120mgER Tab.7911Tiazac XCBIO.79112005-05-250409180mgER Tab1.0501Tiazac XCBIO1.05012005-05-250410240mgER Tab1.3929Tiazac XCBIO1.39292005-05-250411300mgER Tab1.3929Tiazac XCBIO1.39292005-05-250412360mgER Tab1.3929Tiazac XCBIO1.39292005-05-250413120mgLA Cap.6365.6365Cardizem CDBIO1.41141.41141996-10-01Ratio-Diltiazem CDRPH.6366.63661997-04-10Apo-Diltiaz CDAPX.6366.63661997-08-28Novo-Diltazem CDNOP.6366.63662001-06-07Sandoz Diltiazem CDSDZ.6366.63662001-10-11Gen-Diltiazem CDGEN.6366.63662004-09-140414180mgLA Cap.8450.8450Cardizem CDBIO1.87351.87351996-10-01Ratio-Diltiazem CDRPH.8450.84501997-04-10Apo-Diltiaz CDAPX.8450.84501997-08-28Novo-Diltazem CDNOP.8450.84502001-06-07Sandoz Diltiazem CDSDZ.8450.84502001-10-11Gen-Diltiazem CDGEN.8450.84502004-09-140415240mgLA Cap1.12081.1208Cardizem CDBIO2.48502.48501996-10-01Ratio-Diltiazem CDRPH1.12081.12081997-04-10Apo-Diltiaz CDAPX1.12081.12081997-08-28Novo-Diltazem CDNOP1.12081.12082001-06-07Sandoz Diltiazem CDSDZ1.12081.12082001-10-11Gen-Diltiazem CDGEN1.12081.12082004-09-140416300mgLA Cap1.40101.4010Cardizem CDBIO3.10633.10631996-10-01Apo-Diltiaz CDAPX1.40101.40101997-04-10Ratio-Diltiazem CDRPH1.40101.40101997-04-10Novo-Diltazem CDNOP1.40101.40102001-06-07Sandoz Diltiazem CDSDZ1.40101.40102001-10-11Gen-Diltiazem CDGEN1.40101.40102004-09-14041760mgLA Cap.6369.6369Cardizem-SRCRY1998-09-18Apo-Diltiaz SRAPX.6369.63691998-12-31041890mgLA Cap.8453.8453Cardizem-SRCRY2001-10-11Apo-Diltiaz SRAPX.8453.84531998-12-310419120mgLA Cap1.12131.1213Cardizem-SRCRY2001-10-11Apo-Diltiaz SRAPX1.12131.12131998-12-310420120mgSR Cap.4043.4043TiazacBIO.8533.85331998-12-31Sandoz Diltiazem TSDZ.4043.40432006-01-24Novo-Diltiazem HCL ERNOP.4043.40432006-03-01Apo-Diltiaz TZAPX.4043.40432009-01-300421180mgSR Cap.5366.5366TiazacBIO1.15561.15561998-12-31Sandoz Diltiazem TSDZ.5366.53662006-01-24Novo-Diltiazem HCL ERNOP.5366.53662006-03-01Apo-Diltiaz TZAPX.5366.53662009-01-300422240mgSR Cap.7118.7118TiazacBIO1.53281.53281998-12-31Sandoz Diltiazem TSDZ.7118.71182006-01-24Novo-Diltiazem HCL ERNOP.7118.71182006-03-01Apo-Diltiaz TZAPX.7118.71182009-01-300423300mgSR Cap.8897.8897TiazacBIO1.88781.88781998-12-31Sandoz Diltiazem TSDZ.8897.88972006-01-24Novo-Diltiazem HCL ERNOP.8897.88972006-03-01Apo-Diltiaz TZAPX.8897.88972009-01-300424360mgSR Cap1.07321.0732TiazacBIO2.31122.31121998-12-31Sandoz Diltiazem TSDZ1.07321.07322006-01-24Novo-Diltiazem HCL ERNOP1.07321.07322006-03-01Apo-Diltiaz TZAPX1.07321.07322009-01-30042530mgTab.1866Apo-DiltiazAPX.18661996-10-01Novo-DiltazemNOP.18661996-10-01Nu-DiltiazNXP.18661996-10-01CardizemBIO.38261996-10-01042660mgTab.3273Apo-DiltiazAPX.32731996-10-01Novo-DiltazemNOP.32731996-10-01Nu-DiltiazNXP.32731996-10-01CardizemBIO.67111996-10-01DISOPYRAMIDE0427100mgCap.2673NorpaceRBT1996-10-01RythmodanSAV.26732004-07-200428150mgCap.3778NorpaceRBT1996-10-01RythmodanSAV.37782004-07-20FLECAINIDE ACETATE042950mgTab.3956TambocorGRA.52741996-10-01Apo-FlecainideAPX.39562006-07-190430100mgTab.7912TambocorGRA1.05491996-10-01Apo-FlecainideAPX.79122006-07-19METOPROLOL TARTRATE0431100mgLA Tab.1415Lopresor SRNOV.29722001-10-11Apo-Metoprolol SRAPX.14152007-11-10Sandoz Metoprolol SRSDZ.14152008-06-270432200mgLA Tab.2568Lopresor SRNOV.53922001-10-11Apo-Metoprolol SRAPX.25682007-11-10Sandoz Metoprolol SRSDZ.25682008-06-27043350mgTab.0968.1936LopresorNOV.2495.49901996-10-01BetalocAZC.2315.46301996-10-01Apo-MetoprololAPX.0968.19361996-10-01Novo-MetoprolNOP.0968.19361996-10-01Apo-Metoprolol (Type L)APX.0968.19361996-10-01Novo-Metoprol (Uncoated)NOP.0968.19361996-10-01Nu-MetopNXP.1080.21601996-10-01Gen-Metoprolol (Type L)GEN.0968.19361996-10-01PMS-Metoprolol-LPMS.0968.19361998-12-31Sandoz Metoprolol (Type L)SDZ.0968.19362004-07-200434100mgTab.1747.3494LopresorNOV.54421.08841996-10-01BetalocAZC.3965.79301996-10-01Apo-MetoprololAPX.1747.34941996-10-01Novo-MetoprolNOP.1747.34941996-10-01Apo-Metoprolol (Type L)APX.1747.34941996-10-01Novo-Metoprol (Uncoated)NOP.1747.34941996-10-01Nu-MetopNXP.1830.36601996-10-01Gen-Metoprolol (Type L)GEN.1747.34941996-10-01PMS-Metoprolol-LPMS.1747.34941998-12-31Sandoz Metoprolol (Type L)SDZ.1747.34942004-07-20MEXILETINE HCL0435100mgCap.8162MexitilBOE1996-10-01Novo-MexiletineNOP.81621998-12-310436200mgCap1.0930MexitilBOE1996-10-01Novo-MexiletineNOP1.09301998-12-31NADOLOL043740mgTab.2465.2465CorgardBQU1996-10-01Apo-NadolAPX.2465.24651996-10-01Novo-NadololNOP.2465.24651996-10-01043880mgTab.3515.7030CorgardBQU1996-10-01Apo-NadolAPX.3515.70301996-10-01Novo-NadololNOP.3515.70301996-10-010439160mgTab.6595.6595CorgardBQU1996-10-01Apo-NadolAPX.6595.65951996-10-01NIFEDIPINE04405mgCap.3679Apo-NifedAPX.36791996-10-01AdalatBAH1996-10-01044110mgCap.4877Rapid absorption of liquid nifedipine from pulvules can cause severe hypotension and aggravation of myocardial or cerebral ischemia.Apo-NifedAPX.48771996-10-01AdalatBAH1996-10-01PROCAINAMIDE HCL0442250mgLA Tab.3000Procan SRERF.30001996-10-010443500mgLA Tab.5000Procan SRERF.50001996-10-010444750mgLA Tab.8050Procan SRERF.80501996-10-01PROPAFENONE HCL0445150mgTab.3395RythmolABB1.12971996-10-01Apo-PropafenoneAPX.33952001-10-11Gen-PropafenoneGEN.33952003-01-30PMS-PropafenonePMS.33952008-04-090446300mgTab.5985RythmolABB1.99131996-10-01Apo-PropafenoneAPX.59852001-10-11Gen-PropafenoneGEN.59852003-01-30PMS-PropafenonePMS.59852008-04-09PROPRANOLOL044710mgTab.0192Apo-PropranololAPX.01921996-10-01Novo-PranolNOP.01921996-10-01PMS-PropranololPMS.01921996-10-01InderalWAY1996-10-01044820mgTab.0346Apo-PropranololAPX.03461996-10-01Novo-PranolNOP.03461996-10-01InderalWAY1996-10-01044940mgTab.0348.0696Apo-PropranololAPX.0348.06961996-10-01Novo-PranolNOP.0348.06961996-10-01PMS-PropranololPMS.0348.06961996-10-01Inderal-40AYE1996-10-01045080mgTab.0585.1170Apo-PropranololAPX.0585.11701996-10-01Novo-PranolNOP.0585.11701996-10-01PMS-PropranololPMS.0585.11701996-10-01InderalWAY1997-02-040451120mgTab.3091.6182Apo-PropranololAPX.3091.61821996-10-01InderalWAY1997-02-04SOTALOL HCL045280mgTabSotacorBQU2007-12-19Ratio-SotalolRPH2007-12-19Apo-SotalolAPX2007-12-19Gen-SotalolGEN2007-12-19Novo-SotalolNOP2007-12-19PMS-SotalolPMS2007-12-19Sandoz SotalolSDZ2007-12-19Co SotalolCOB2007-12-190453160mgTab.6492SotacorBQU1996-10-01Ratio-SotalolRPH.64921996-10-01Nu-SotalolNXP.64921996-10-01Apo-SotalolAPX.64921996-10-01Gen-SotalolGEN.64921999-04-15Novo-SotalolNOP.64921998-12-31Rhoxal-SotalolSDZ.64922000-01-17PMS-SotalolPMS.64921999-04-15Sandoz SotalolSDZ.64922005-01-25Co SotalolCOB.64922006-10-23TIMOLOL MALEATE04545mgTab.1649.3298BlocadrenFRS1996-10-01Apo-TimolAPX.1649.32981996-10-01Novo-TimolNOP.1649.32981996-10-01Nu-TimololNXP.1649.32981996-10-01045510mgTab.2572.5144BlocadrenFRS1996-10-01Apo-TimolAPX.2572.51441996-10-01Novo-TimolNOP.2572.51441996-10-01Nu-TimololNXP.2572.51441996-10-01045620mgTab.50051.0010BlocadrenFRS1996-10-01Apo-TimolAPX.50051.00101996-10-01Novo-TimolNOP.50051.00101996-10-01Nu-TimololNXP.50051.00101996-10-01VERAPAMIL HCL045780mgTab.2735.8205IsoptinABB1996-10-01Apo-VerapAPX.2735.82051996-10-01Nu-VerapNXP.2735.82051996-10-01Gen-VerapamilGEN.2735.82051999-04-150458120mgTab.42501.2750IsoptinABB1996-10-01Apo-VerapAPX.42501.27501996-10-01Nu-VerapNXP.42501.27501996-10-01Gen-VerapamilGEN.42501.27501999-04-15ANTILIPEMIC DRUGSNicotinic acid is the most cost-effective therapy for hyperlipidemia and is tolerated in approximately 80% of patients with adequate warning about expected flushing which disappears after five days in most cases; regular ASA will substantially reduce flushing. Bile acid sequestrants are more costly than fibrates or HMG-CoA reductase inhibitors.AMLODIPINE BESYLATE / ATORVASTATIN CALCIUM04595mg/10mgTab2.4500Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Caduet.CaduetPFI2.45002006-10-2304605mg/20mgTab3.2000Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Caduet.CaduetPFI3.20002006-10-2304615mg/40mgTab3.2000Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Caduet.CaduetPFI3.20002006-10-2304625mg/80mgTab3.2000Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Caduet.CaduetPFI3.20002006-10-23046310mg/10mgTab2.4500Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Caduet.CaduetPFI2.45002006-10-23046410mg/20mgTab3.2000Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Caduet.CaduetPFI3.20002006-10-23046510mg/40mgTab3.2000Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Caduet.CaduetPFI3.20002006-10-23046610mg/80mgTab3.2000Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Caduet.CaduetPFI3.20002006-10-23ATORVASTATIN CALCIUM046710mgTab1.6640LipitorPFI1.66401997-08-28046820mgTab2.0800LipitorPFI2.08001997-08-28046940mgTab2.2360LipitorPFI2.23601997-08-28047080mgTab2.2360LipitorPFI2.23602002-04-04BEZAFIBRATE0471400mgSR Tab1.6000BezalipAGP1.60001996-10-010472200mgTab.8833BezalipHLR1996-10-01PMS-BezafibratePMS.88332000-07-17CHOLESTYRAMINE RESIN0473Oral Pd-Pouch Pk1.3167Questran 9g PkBQU1996-10-01PMS-Cholestyramine Sugar Free 5g PkPMS1.31671996-10-01Questran Light 4g PkBQU2004-07-20PMS-Cholestyramine 9g PkPMS1.31671997-04-10CLOFIBRATE0474500mgCapAtromid-SAYE1996-10-01Novo-FibrateNOP1996-10-01COLESTIPOL HCLCombining psyllium with Colestid therapy improves the efficacy, and decreases costs, of antilipemic treatment.0475Gran-5g Pk.8510Colestid RegularPFI.85101996-10-010476Gran-7.5g Pk.8510Colestid OrangePFI.85101996-10-01EZETIMIBE047710mgTab1.7248EzetrolMFS1.72482004-04-06For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.LU Authorization Period: Indefinite.For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.LU Authorization Period: Indefinite.FENOFIBRATE0478100mgCap.6105LipidilJOU1996-10-01Apo-FenofibrateAPX.61051996-12-19047967mgCapLipidil MicroFOU2008-01-15Apo-Feno-MicroAPX2008-01-15Novo-Fenofibrate MicronizedNOP2008-11-040480200mgCap1.0890Lipidil MicroSPH1.08901996-10-01Apo-Feno-MicroAPX1.08902000-01-17Gen-Fenofibrate MicroGEN1.08902000-01-17Novo-Fenofibrate MicronizedNOP1.08902002-04-04Ratio-Fenofibrate MCRPH1.08902004-07-20PMS-Fenofibrate MicroPMS1.08902007-01-020481100mgTabLipidil SupraLAF2008-11-04Apo-Feno-SuperAPX2008-12-03Sandoz Fenofibrate SSDZ2009-08-18Novo-Fenofibrate-SNOP2008-11-040482160mgTab.5500Lipidil SupraSPH1.24632001-06-07Apo-Feno-SuperAPX.55002006-06-14FenomaxORY.55002008-11-04Sandoz Fenofibrate SSDZ.55002007-03-09Novo-Fenofibrate-SNOP.55002007-06-06048348mgTab.4100Lipidil EZFOU.41002006-10-230484145mgTab1.0500Lipidil EZFOU1.05002006-10-23FLUVASTATIN SODIUM048520mgCap.8510LescolNOV.85101996-10-01048640mgCap1.1949LescolNOV1.19491996-10-01048780mgER Tab1.4414Lescol XLNOV1.44142005-02-22GEMFIBROZIL0488300mgCap.2352LopidPFI.48921996-10-01Apo-GemfibrozilAPX.23521996-10-01Gen-GemfibrozilGEN.23521997-08-28PMS-GemfibrozilPMS.23522000-01-17Novo-GemfibrozilNOP.23522001-06-070489600mgTabLopidPFI2008-02-12Apo-GemfibrozilAPX2008-02-12Novo-GemfibrozilNOP2008-02-12PMS-GemfibrozilPMS2008-02-12Gen-GemfibrozilGEN2008-02-12LOVASTATIN049020mgTab.8657MevacorMFC1.96751996-10-01Apo-LovastatinAPX.86571997-08-28Gen-LovastatinGEN.86572001-06-07Ratio-LovastatinRPH.86572003-01-30PMS-LovastatinPMS.86572003-01-30Novo-LovastatinNOP.86572003-04-16Sandoz LovastatinSDZ.86572003-09-04Co-LovastatinCOB.86572004-09-14Ran-LovastatinRAN.86572005-12-06049140mgTab1.5968MevacorMFC3.59391996-10-01Apo-LovastatinAPX1.59681997-08-28Gen-LovastatinGEN1.59682001-06-07Ratio-LovastatinRPH1.59682003-01-30PMS-LovastatinPMS1.59682003-01-30Novo-LovastatinNOP1.59682003-04-16Sandoz LovastatinSDZ1.59682003-09-04Co-LovastatinCOB1.59682004-09-14Ran-LovastatinRAN1.59682005-12-06NIACIN0492500mgER Tab1.1975Note: For the treatment of dyslipidemia in patients who, after an adequate trial of crystalline niacin(defined as at least 1 month duration during which time appropriate dose titration, use of ASA and patient counseling have occurred), are unable to continue taking crystalline niacin because of intractable and intolerable side effects.NiaspanSEP1.19752009-01-300493750mgER Tab1.1975Note: For the treatment of dyslipidemia in patients who, after an adequate trial of crystalline niacin(defined as at least 1 month duration during which time appropriate dose titration, use of ASA and patient counseling have occurred), are unable to continue taking crystalline niacin because of intractable and intolerable side effects.NiaspanSEP1.19752009-01-3004941000mgER Tab1.1975Note: For the treatment of dyslipidemia in patients who, after an adequate trial of crystalline niacin(defined as at least 1 month duration during which time appropriate dose titration, use of ASA and patient counseling have occurred), are unable to continue taking crystalline niacin because of intractable and intolerable side effects.NiaspanSEP1.19752009-01-30PRAVASTATIN SODIUM049510mgTab.7567PravacholBQU.75671996-10-01Apo-PravastatinAPX.75672001-06-07Nu-PravastatinNXP.75672002-07-29Ratio-PravastatinRPH.75672003-09-04Novo-PravastatinNOP.75672003-09-04PMS-PravastatinPMS.75672004-04-06Sandoz PravastatinSDZ.75672004-04-06Co PravastatinCOB.75672004-04-06Gen-PravastatinGEN.75672005-11-08Ran-PravastatinRAN.75672007-09-04049620mgTab.8925PravacholBQU.89251996-10-01Apo-PravastatinAPX.89252001-06-07Nu-PravastatinNXP.89252002-07-29Ratio-PravastatinRPH.89252003-09-04Novo-PravastatinNOP.89252003-09-04PMS-PravastatinPMS.89252004-04-06Sandoz PravastatinSDZ.89252004-04-06Co PravastatinCOB.89252004-04-06Gen-PravastatinGEN.89252005-11-08Ran-PravastatinRAN.89252007-09-04049740mgTab1.0750PravacholBQU1.07501997-08-28Apo-PravastatinAPX1.07502001-06-07Nu-PravastatinNXP1.07502002-07-29Ratio-PravastatinRPH1.07502003-09-04Novo-PravastatinNOP1.07502003-09-04PMS-PravastatinPMS1.07502004-04-06Sandoz PravastatinSDZ1.07502004-04-06Co PravastatinCOB1.07502004-04-06Gen-PravastatinGEN1.07502005-11-08Ran-PravastatinRAN1.07502007-09-04ROSUVASTATIN CALCIUM04985mgTab1.2900CrestorAZC1.29002007-01-02049910mgTab1.3600CrestorAZC1.36002003-09-04050020mgTab1.7000CrestorAZC1.70002003-09-04050140mgTab1.9900CrestorAZC1.99002003-09-04SIMVASTATIN05025mgTab.4500ZocorMFC1.02251996-10-01Gen-SimvastatinGEN.45002003-04-16Apo-SimvastatinAPX.45002003-04-16Ratio-SimvastatinRPH.45002004-04-06Co-SimvastatinCOB.45002004-04-06Novo-SimvastatinNOP.45002004-07-20PMS-SimvastatinPMS.45002006-04-04050310mgTab.8900ZocorMFC2.02321996-10-01Gen-SimvastatinGEN.89002003-04-16Apo-SimvastatinAPX.89002003-04-16Ratio-SimvastatinRPH.89002004-04-06Sandoz SimvastatinSDZ.89002004-04-06Co-SimvastatinCOB.89002004-04-06Novo-SimvastatinNOP.89002004-07-20Taro-SimvastatinTAR.89002005-10-06PMS-SimvastatinPMS.89002006-04-04050420mgTab1.1000ZocorMFC2.50041996-10-01Gen-SimvastatinGEN1.10002003-04-16Apo-SimvastatinAPX1.10002003-04-16Ratio-SimvastatinRPH1.10002004-04-06Sandoz SimvastatinSDZ1.10002004-04-06Co-SimvastatinCOB1.10002004-04-06Novo-SimvastatinNOP1.10002004-07-20Taro-SimvastatinTAR1.10002005-10-06PMS-SimvastatinPMS1.10002006-04-04050540mgTab1.1000ZocorMFC2.50041996-12-19Gen-SimvastatinGEN1.10002003-04-16Apo-SimvastatinAPX1.10002003-04-16Ratio-SimvastatinRPH1.10002004-04-06Sandoz SimvastatinSDZ1.10002004-04-06Co-SimvastatinCOB1.10002004-04-06Novo-SimvastatinNOP1.10002004-07-20Taro-SimvastatinTAR1.10002005-10-06PMS-SimvastatinPMS1.10002006-04-04050680mgTab1.1000ZocorMFC2.50042000-04-17Gen-SimvastatinGEN1.10002003-04-16Apo-SimvastatinAPX1.10002003-04-16Ratio-SimvastatinRPH1.10002004-04-06Sandoz SimvastatinSDZ1.10002004-04-06Co-SimvastatinCOB1.10002004-04-06Novo-SimvastatinNOP1.10002004-07-20PMS-SimvastatinPMS1.10002006-04-04HYPOTENSIVE DRUGS (FOR DIURETICS SEE 40:28)ALISKIREN0507150mgTab1.1857NOTE: For patients with moderate hypertension who have not achieved blood pressure targets while on maximally optimized therapy with a thiazide-diuretic AND an Angiotensin Converting Enzyme Inhibitor (ACE-I) or a thiazide-diuretic AND Angiotensin II Receptor Blocker (ARB).RasilezNOV1.18572008-12-030508300mgTab1.1857NOTE: For patients with moderate hypertension who have not achieved blood pressure targets while on maximally optimized therapy with a thiazide-diuretic AND an Angiotensin Converting Enzyme Inhibitor (ACE-I) or a thiazide-diuretic AND Angiotensin II Receptor Blocker (ARB).RasilezNOV1.18572008-12-03ATENOLOL & CHLORTHALIDONE050950 & 25mgTab.3195Tenoretic 50/25AZC.63891996-10-01Apo-AtenidoneAPX.31952004-09-14Novo-AtenolthalidoneNOP.31952008-02-120510100 & 25mgTab.5236Tenoretic 100/25AZC1.04711996-10-01Apo-AtenidoneAPX.52362004-09-14Novo-AtenolthalidoneNOP.52362008-02-12BENAZEPRIL05115mgTab.4722.4722LotensinNOV.7436.74361996-10-01Apo-BenazeprilAPX.4722.47222007-10-03051210mgTab.5583.5583LotensinNOV.8793.87931996-10-01Apo-BenazeprilAPX.5583.55832007-10-03051320mgTab.5460.5460LotensinNOV1.00891.00891996-10-01Apo-BenazeprilAPX.5460.54602006-06-14CANDESARTAN CILEXETIL05144mgTab.6800AtacandAZC.68002006-04-1905158mgTab1.1400AtacandAZC1.14001999-09-15051616mgTab1.1400AtacandAZC1.14001999-09-15051732mgTab1.1400AtacandAZC1.14002009-05-20CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE051816mg/12.5mgTab1.1400Atacand PlusAZC1.14002002-07-29CAPTOPRIL051912.5mgTab.2120.6360CapotenBQU.2120.63601996-10-01Apo-CaptoAPX.2120.63601996-10-01Nu-CaptoNXP.2120.63601996-10-01Novo-CaptoprilNOP.2120.63601996-10-01Gen-CaptoprilGEN.2120.63601996-10-01PMS-CaptoprilPMS.2120.63601999-04-15CaptoprilZYN.2120.63602001-06-07052025mgTab.3000.9000CapotenBQU.3000.90001996-10-01Apo-CaptoAPX.3000.90001996-10-01Nu-CaptoNXP.3000.90001996-10-01Novo-CaptoprilNOP.3000.90001996-10-01Gen-CaptoprilGEN.3000.90001996-10-01PMS-CaptoprilPMS.3000.90001999-04-15CaptoprilZYN.3000.90002001-06-07052150mgTab.55901.6770CapotenBQU.55901.67701996-10-01Apo-CaptoAPX.55901.67701996-10-01Nu-CaptoNXP.55901.67701996-10-01Novo-CaptoprilNOP.55901.67701996-10-01Gen-CaptoprilGEN.55901.67701996-10-01PMS-CaptoprilPMS.55901.67701999-04-15CaptoprilZYN.55901.67702001-06-070522100mgTab1.0395CapotenBQU1996-10-01Apo-CaptoAPX1.03951996-10-01Nu-CaptoNXP1.03951996-10-01Novo-CaptoprilNOP1.03951996-10-01Gen-CaptoprilGEN1.03951996-10-01PMS-CaptoprilPMS1.03951999-04-15CaptoprilZYN1.03952001-06-07CILAZAPRIL05231mgTab.2950InhibaceHLR.62291996-10-01Novo-CilazaprilNOP.29502005-06-13PMS-CilazaprilPMS.29502006-08-24Gen-CilazaprilGEN.29502006-09-06Apo-CilazaprilAPX.29502007-03-0905242.5mgTab.3400.3400InhibaceHLR.7179.71791996-10-01Novo-CilazaprilNOP.3400.34002005-06-13PMS-CilazaprilPMS.3400.34002006-08-24Gen-CilazaprilGEN.3400.34002006-09-06Co CilazaprilCOB.3400.34002007-04-02Apo-CilazaprilAPX.3400.34002007-03-0905255mgTab.3950.3950InhibaceHLR.8341.83411996-10-01Novo-CilazaprilNOP.3950.39502005-06-13PMS-CilazaprilPMS.3950.39502006-08-24Gen-CilazaprilGEN.3950.39502006-09-06Co CilazaprilCOB.3950.39502007-04-02Apo-CilazaprilAPX.3950.39502007-03-09CILAZAPRIL & HYDROCHLOROTHIAZIDE05265mg/12.5mgTab.4170Inhibace PlusHLR.83392000-01-17Apo-Cilazapril/HCTZAPX.41702007-01-02Novo-Cilazapril/HCTZNOP.41702009-05-20CLONIDINE HCLSignificant rebound hypertension can occur after missing even one or two doses; this drug should be avoided in patients with cardiovascular fragility or suspected problems with compliance.05270.025mgTabDixaritBOE2007-06-06Apo-ClonidineAPX2007-06-06Novo-ClonidineNOP2008-05-1605280.1mgTab.1358.5432CatapresBOE.1853.74121996-10-01Apo-ClonidineAPX.1358.54321996-10-01Nu-ClonidineNXP.1358.54321996-10-01Novo-ClonidineNOP.1358.54321996-10-0105290.2mgTab.2424.9696CatapresBOE.33061.32241996-10-01Apo-ClonidineAPX.2424.96961996-10-01Nu-ClonidineNXP.2424.96961996-10-01Novo-ClonidineNOP.2424.96961996-10-01DOXAZOSIN MESYLATE05301mgTab.2750.2750Cardura-1AZC.5665.56651996-10-01Gen-DoxazosinGEN.2750.27502000-01-17Apo-DoxazosinAPX.2750.27502000-01-17Novo-DoxazosinNOP.2750.27502001-03-07PMS-DoxazosinPMS.2750.27502002-04-0405312mgTab.3300.3300Cardura-2AZC.6795.67951996-10-01Gen-DoxazosinGEN.3300.33002000-01-17Apo-DoxazosinAPX.3300.33002000-01-17Novo-DoxazosinNOP.3300.33002001-03-07PMS-DoxazosinPMS.3300.33002002-04-0405324mgTab.4290.4290Cardura-4AZC.8835.88351996-10-01Gen-DoxazosinGEN.4290.42902000-01-17Apo-DoxazosinAPX.4290.42902000-01-17Novo-DoxazosinNOP.4290.42902001-03-07PMS-DoxazosinPMS.4290.42902002-04-04ENALAPRIL MALEATE05332.5mgTab.3617.3617VasotecMFC.3617.3617** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.1996-10-01Apo-EnalaprilAPX2007-12-19Co EnalaprilCOB** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.2007-12-19Sandoz EnalaprilSDZ** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.2007-12-19Ratio-EnalaprilRPH** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.2007-12-19Gen-EnalaprilGEN** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.2007-12-19PMS-EnalaprilPMS** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.2008-02-12Taro-EnalaprilTAR** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.2008-01-15Novo-EnalaprilNOP** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.2008-05-1605345mgTab.4279.4279VasotecMFC.4279.4279** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.1996-10-01Apo-EnalaprilAPX2007-12-19Novo-EnalaprilNOP** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.2008-05-16Co EnalaprilCOB** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.2007-12-19Sandoz EnalaprilSDZ** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.2007-12-19Ratio-EnalaprilRPH** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.2007-12-19Gen-EnalaprilGEN** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.2007-12-19PMS-EnalaprilPMS** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.2008-02-12Taro-EnalaprilTAR** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.2008-01-15053510mgTab.5142.5142VasotecMFC.5142.5142** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.1996-10-01Apo-EnalaprilAPX2007-12-19Novo-EnalaprilNOP** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.2008-05-16Co EnalaprilCOB** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.2007-12-19Sandoz EnalaprilSDZ** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.2007-12-19Ratio-EnalaprilRPH** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.2007-12-19Gen-EnalaprilGEN** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.2007-12-19PMS-EnalaprilPMS** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.2008-02-12Taro-EnalaprilTAR** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.2008-01-15053620mgTab.6204.6204VasotecMFC.6204.6204** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.1996-10-01Apo-EnalaprilAPX2007-12-19Novo-EnalaprilNOP** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.2008-05-16Co EnalaprilCOB** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.2007-12-19Sandoz EnalaprilSDZ** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.2007-12-19Ratio-EnalaprilRPH** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.2007-12-19Gen-EnalaprilGEN** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.2007-12-19PMS-EnalaprilPMS** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.2008-02-12Taro-EnalaprilTAR** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.2008-01-15EPROSARTAN MESYLATE0537400mgTab.7003TevetenSPH.70032002-07-290538600mgTab1.0510TevetenSPH1.05102002-07-29EPROSARTAN MESYLATE & HYDROCHLOROTHIAZIDE0539600mg & 12.5mgTab1.0510Teveten PlusSPH1.05102005-05-25FELODIPINEGrapefruit juice or erythromycin triple the blood levels of felodipine and markedly increase both efficacy and adverse effects. Other dihydropyridines are affected to differing degrees by grapefruit juice.05402.5mgER Tab.5087PlendilAZC.50871996-10-0105415mgER Tab.4620.4620PlendilAZC.6797.67971996-10-01Sandoz FelodipineSDZ.4620.46202007-01-02054210mgER Tab.6925.6925PlendilAZC1.01971.01971996-10-01Sandoz FelodipineSDZ.6925.69252007-01-0205432.5mgSR Tab.5301RenedilSAV.53011999-01-0705445mgSR Tab.4620.4620RenedilSAV.7228.72281999-01-07Sandoz FelodipineSDZ.4620.46202007-01-02054510mgSR Tab.6925.6925RenedilSAV1.08341.08341999-01-07Sandoz FelodipineSDZ.6925.69252007-01-02FOSINOPRIL SODIUM054610mgTab.3950.3950MonoprilBQU.8710.87101996-10-01Lin-FosinoprilLON.3950.39502004-07-20Novo-FosinoprilNOP.3950.39502004-04-06PMS-FosinoprilPMS.3950.39502005-07-14Gen-FosinoprilGEN.3950.39502005-01-25Apo-FosinoprilAPX.3950.39502005-07-14054720mgTab.4750.4750MonoprilBQU1.04751.04751996-10-01Lin-FosinoprilLON.4750.47502004-07-20Novo-FosinoprilNOP.4750.47502004-04-06PMS-FosinoprilPMS.4750.47502005-07-14Gen-FosinoprilGEN.4750.47502005-01-25Apo-FosinoprilAPX.4750.47502005-07-14HYDRALAZINE HCL054820mg/mLInj Sol-1mL Pk11.6500ApresolineSTE11.65001996-10-01054910mgTab.1026.4104ApresolineNOV1996-10-01Apo-HydralazineAPX.1026.41041996-10-01055025mgTab.1644.6576ApresolineSTE1996-10-01Apo-HydralazineAPX.1644.65761996-10-01Novo-HylazinNOP.1644.65761996-10-01055150mgTab.25271.0108ApresolineNOV1996-10-01Apo-HydralazineAPX.25271.01081996-10-01Novo-HylazinNOP.25271.01081996-10-01IRBESARTAN055275mgTab1.2098AvaproSAV1.20981999-04-150553150mgTab1.2098AvaproSAV1.20981999-04-150554300mgTab1.2098AvaproSAV1.20981999-04-15IRBESARTAN & HYDROCHLOROTHIAZIDE0555150 & 12.5mgTab1.2098AvalideSAV1.20982001-03-070556300 & 12.5mgTab1.2098AvalideSAV1.20982001-03-070557300 & 25mgTab1.2015AvalideSAV1.20152007-03-09LABETALOL HCL0558100mgTab.2024TrandatePAL.25481998-03-17Apo-LabetalolAPX.20242001-10-110559200mgTab.3437TrandatePAL.45051998-03-17Apo-LabetalolAPX.34372001-10-11LISINOPRIL05605mgTab.2694.2694PrinivilMFC.5713.57131996-10-01Ratio-Lisinopril PRPH.2694.26942007-12-19Novo-Lisinopril (Type P)NOP.2694.26942007-12-19Apo-LisinoprilAPX.2694.26941999-04-15Sandoz LisinoprilSDZ.2694.26942007-12-19056110mgTab.3237.3237PrinivilMFC.6864.68641996-10-01Ratio-Lisinopril PRPH.3237.32372007-12-19Novo-Lisinopril (Type P)NOP.3237.32372007-12-19Apo-LisinoprilAPX.3237.32372001-06-07Sandoz LisinoprilSDZ.3237.32372007-12-19056220mgTab.3890.3890PrinivilMFC.8253.82531996-10-01Ratio-Lisinopril PRPH.3890.38902007-12-19Novo-Lisinopril (Type P)NOP.3890.38902007-12-19Apo-LisinoprilAPX.3890.38902001-06-07Sandoz LisinoprilSDZ.3890.38902007-12-1905635mgTab.2694.2694ZestrilAZC.5388.53881996-10-01Apo-LisinoprilAPX.2694.26941997-08-28Co LisinoprilCOB.2694.26942007-12-19Gen-LisinoprilGEN.2694.26942007-12-19Novo-Lisinopril (Type Z)NOP.2694.26942007-12-19Sandoz LisinoprilSDZ.2694.26942007-12-19PMS-LisinoprilPMS.2694.26942007-12-19Ran-LisinoprilRAN.2694.26942007-12-19Ratio-Lisinopril ZRPH.2694.26942007-12-19056410mgTab.3237.3237ZestrilAZC.6474.64741996-10-01Apo-LisinoprilAPX.3237.32372001-06-07Co LisinoprilCOB.3237.32372007-12-19Gen-LisinoprilGEN.3237.32372007-12-19Novo-Lisinopril (Type Z)NOP.3237.32372007-12-19Sandoz LisinoprilSDZ.3237.32372007-12-19PMS-LisinoprilPMS.3237.32372007-12-19Ran-LisinoprilRAN.3237.32372007-12-19Ratio-Lisinopril ZRPH.3237.32372007-12-19056520mgTab.3890.3890ZestrilAZC.7779.77791996-10-01Apo-LisinoprilAPX.3890.38902001-06-07Co LisinoprilCOB.3890.38902007-12-19Gen-LisinoprilGEN.3890.38902007-12-19Novo-Lisinopril (Type Z)NOP.3890.38902007-12-19Sandoz LisinoprilSDZ.3890.38902007-12-19PMS-LisinoprilPMS.3890.38902007-12-19Ran-LisinoprilRAN.3890.38902007-12-19Ratio-Lisinopril ZRPH.3890.38902007-12-19LISINOPRIL & HYDROCHLOROTHIAZIDE056610mg & 12.5mgTab.4168ZestoreticAZC.83351996-10-01Apo-Lisinopril/HCTZAPX.41682007-10-03Gen-Lisinopril HCTZGEN.41682008-01-15Novo-Lisinopril/HCTZ (Type Z)NOP.41682008-01-15Sandoz Lisinopril HCTSDZ.41682008-01-15056710mg & 12.5mgTab.3334PrinzideMFC.70741996-10-01Novo-Lisinopril/HCTZ (Type P)NOP.33342008-01-15056820mg & 12.5mgTab.4006PrinzideMFC.85001996-10-01Novo-Lisinopril/HCTZ (Type P)NOP.40062008-01-15056920mg & 12.5mgTab.5008ZestoreticAZC1.00161996-10-01Apo-Lisinopril/HCTZAPX.50082008-01-15Gen-Lisinopril HCTZGEN.50082008-01-15Novo-Lisinopril/HCTZ (Type Z)NOP.50082008-01-15Sandoz Lisinopril HCTSDZ.50082008-01-15057020mg & 25mgTabZestoreticAZC2008-08-28Apo-Lisinopril/HCTZAPX2008-08-28Gen-Lisinopril HCTZGEN2008-08-28Novo-Lisinopril/HCTZ (Type Z)NOP2008-08-28Sandoz Lisinopril HCTSDZ2008-12-23057120mg/25mgTabPrinzideMFC2008-08-28Novo-Lisinopril/HCTZ (Type P)NOP2008-08-28LOSARTAN POTASSIUM057225mgTab1.2500CozaarMFC1.25001996-10-01057350mgTab1.2500CozaarMFC1.25001996-10-010574100mgTab1.2500CozaarMFC1.25001999-04-15LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE057550mg/12.5mgTab1.2500HyzaarMFC1.25002000-11-300576100mg/25mgTab1.2500Hyzaar DSMFC1.25002000-11-30METHYLDOPA0577125mgTab.0989.3956AldometMSD1996-10-01Apo-MethyldopaAPX.0989.39561996-10-010578250mgTab.1433.5732AldometMSD2002-11-22Apo-MethyldopaAPX.1433.57321996-10-010579500mgTab.2537.5074AldometMSD1996-10-01Apo-MethyldopaAPX.2537.50741996-10-01MINOXIDIL05802.5mgTab.3288LonitenPFI.32881996-10-01058110mgTab.7250LonitenPFI.72501996-10-01NIFEDIPINE058220mgER Tab1.1889Adalat XLBAY1.18891999-04-15058330mgER Tab1.18891.1889Adalat XLBAY1.18891.18891996-10-01058460mgER Tab.9374.9374Adalat XLBAY1.87471.87471996-10-01Gen-Nifedipine Extended ReleaseGEN.9374.93742009-03-02058510mgLA Tab.4432.8864Adalat PA 10BAH1997-08-28Apo-Nifed PAAPX.4432.88641998-12-31058620mgLA Tab.69301.3860Adalat PA 20BAH1997-08-28Apo-Nifed PAAPX.69301.38601997-08-28PERINDOPRIL ERBUMINE05872mgTab.6233CoversylSEV.62331996-10-0105884mgTab.7800CoversylSEV.78001996-10-0105898mgTab1.0920CoversylSEV1.09202004-07-20Apo-PerindoprilAPX2008-03-25PERINDOPRIL ERBUMINE & INDAPAMIDE05902mg & 0.625mgTab.8207Coversyl Plus LDSEV.82072007-04-0205914mg & 1.25mgTab.9763Coversyl PlusSEV.97632007-04-02PINDOLOL05925mgTab.2023.4046ViskenNOV.54421.08841996-10-01Apo-PindolAPX.2023.40461996-10-01Novo-PindolNOP.2023.40461996-10-01Nu-PindolNXP.2023.40461996-10-01Gen-PindololGEN.2023.40461996-10-01PMS-PindololPMS.2023.40461999-04-15Sandoz PindololSDZ.2023.40462006-07-19059310mgTab.3490.6980ViskenNOV.92931.85861996-10-01Apo-PindolAPX.3490.69801996-10-01Novo-PindolNOP.3490.69801996-10-01Nu-PindolNXP.3490.69801996-10-01Gen-PindololGEN.3490.69801996-10-01PMS-PindololPMS.3490.69801999-04-15Sandoz PindololSDZ.3490.69802006-07-19059415mgTab.51281.0256ViskenNOV1.34812.69621996-10-01Apo-PindolAPX.51281.02561996-10-01Novo-PindolNOP.51281.02561996-10-01Nu-PindolNXP.51281.02561996-10-01Gen-PindololGEN.51281.02561996-10-01PMS-PindololPMS.51281.02561999-04-15Sandoz PindololSDZ.51281.02562006-07-19PINDOLOL & HYDROCHLOROTHIAZIDE059510mg & 25mgTab.8341Viskazide 10/25NOV.83411996-10-01059610mg & 50mgTab.8341Viskazide 10/50NOV.83411996-10-01PRAZOSIN HCL05971mgTab.1371.2742MinipressPFI.2743.54861996-10-01Apo-PrazoAPX.1371.27421996-10-01Nu-PrazoNXP.1371.27421996-10-01Novo-PrazinNOP.1371.27421996-10-0105982mgTab.1862.3724MinipressPFI.3725.74501996-10-01Apo-PrazoAPX.1862.37241996-10-01Nu-PrazoNXP.1862.37241996-10-01Novo-PrazinNOP.1862.37241996-10-0105995mgTab.2560.5120MinipressPFI.51211.02421996-10-01Apo-PrazoAPX.2560.51201996-10-01Nu-PrazoNXP.2560.51201996-10-01Novo-PrazinNOP.2560.51201996-10-01QUINAPRIL HCL06005mgTab.8543.8543AccuprilPFI.8543.85431996-10-01060110mgTab.8543.8543AccuprilPFI.8543.85431996-10-01060220mgTab.8543.8543AccuprilPFI.8543.85431996-10-01060340mgTab.8543.8543AccuprilPFI.8543.85431996-10-01QUINAPRIL HCL & HYDROCHLOROTHIAZIDE060410mg & 12.5mgTab.8543AccureticPFI.85432000-07-17060520mg & 12.5mgTab.8543AccureticPFI.85432000-07-17060620mg & 25mgTab.8504AccureticPFI.85042004-04-06RAMIPRIL06071.25mg.3250Altace CapSAV.69331999-01-06Apo-Ramipril CapAPX.32502007-03-09Ratio-Ramipril CapRPH.32502007-03-09Sandoz Ramipril TabSDZ.32502008-04-09Co Ramipril CapCOB.32502007-11-10Ramipril CapRIA.32502008-08-28Gen-Ramipril CapGEN.32502008-08-28Ran-Ramipril CapRAN.32502008-11-0406082.5mg.3750Altace CapSAV.79991999-01-06Novo-Ramipril CapNOP.37502007-06-06Apo-Ramipril CapAPX.37502007-03-09Ramipril CapRIA.37502008-08-28Ratio-Ramipril CapRPH.37502007-03-09Sandoz Ramipril TabSDZ.37502008-04-09Co Ramipril CapCOB.37502007-12-19Gen-Ramipril CapGEN.37502008-08-28Ran-Ramipril CapRAN.37502008-11-0406095mg.3750Altace CapSAV.79991999-01-06Novo-Ramipril CapNOP.37502007-06-06Apo-Ramipril CapAPX.37502007-03-09Ramipril CapRIA.37502008-08-28Ratio-Ramipril CapRPH.37502007-03-09Sandoz Ramipril TabSDZ.37502008-04-09Co Ramipril CapCOB.37502007-12-19Gen-Ramipril CapGEN.37502008-08-28Ran-Ramipril CapRAN.37502008-11-04061010mg.4750Altace CapSAV1.01321999-01-06Novo-Ramipril CapNOP.47502007-06-06Apo-Ramipril CapAPX.47502007-03-09Ramipril CapRIA.47502008-08-28Ratio-Ramipril CapRPH.47502007-03-09Sandoz Ramipril TabSDZ.47502008-04-09Co Ramipril CapCOB.47502007-11-10Gen-Ramipril CapGEN.47502008-08-28Ran-Ramipril CapRAN.47502008-11-04061115mgCapAltaceSAV2009-06-23Ratio-RamiprilRPH2009-06-23Apo-RamiprilAPX2009-06-23RAMIPRIL & HYDROCHLOROTHIAZIDE06122.5mg & 12.5mgTab.7500Altace HCTSAV.75002007-06-0606135mg & 12.5mgTab.7650Altace HCTSAV.76502007-06-0606145mg & 25mgTab.7650Altace HCTSAV.76502007-06-06061510mg & 12.5mgTab.9689Altace HCTSAV.96892007-06-06061610mg & 25mgTab.9689Altace HCTSAV.96892007-06-06TELMISARTAN061740mgTab1.1296MicardisBOE1.12962000-04-17061880mgTab1.1296MicardisBOE1.12962000-04-17TELMISARTAN & HYDROCHLOROTHIAZIDE061980mg/12.5mgTab1.1296Micardis PlusBOE1.12962002-07-29TERAZOSIN HCL06201mgTab.2770.2770HytrinABB.6991.69911996-10-01Ratio-TerazosinRPH.2770.27701998-12-31Novo-TerazosinNOP.2770.27701999-04-15Nu-TerazosinNXP.2770.27701999-04-15Apo-TerazosinAPX.2770.27701998-12-31PMS-TerazosinPMS.2770.27702001-10-1106212mgTab.3521.3521HytrinABB.8887.88871996-10-01Ratio-TerazosinRPH.3521.35211998-12-31Novo-TerazosinNOP.3521.35211999-04-15Nu-TerazosinNXP.3521.35211999-04-15Apo-TerazosinAPX.3521.35211998-12-31PMS-TerazosinPMS.3521.35212001-10-1106225mgTab.4782.4782HytrinABB1.20691.20691996-10-01Ratio-TerazosinRPH.4782.47821998-12-31Novo-TerazosinNOP.4782.47821999-04-15Nu-TerazosinNXP.4782.47821999-04-15Apo-TerazosinAPX.4782.47821998-12-31PMS-TerazosinPMS.4782.47822001-10-11062310mgTab.7000.7000HytrinABB1.76661.76661996-10-01Ratio-TerazosinRPH.7000.70001998-12-31Novo-TerazosinNOP.7000.70001999-04-15Nu-TerazosinNXP.7000.70001999-04-15Apo-TerazosinAPX.7000.70001998-12-31PMS-TerazosinPMS.7000.70002001-10-11TRANDOLAPRIL06241mgCap.6901MavikABB.69011998-12-3106252mgCap.7931MavikABB.79311998-12-3106264mgCap.9785MavikABB.97852004-07-20VALSARTAN062780mgTab1.1832DiovanNOV1.18322003-09-040628160mgTab1.1832DiovanNOV1.18322003-09-040629320mgTab1.1371DiovanNOV1.13712008-02-12VALSARTAN & HYDROCHLOROTHIAZIDE063080mg/12.5mgTab1.1832Diovan-HCTNOV1.18322001-03-070631160mg/12.5mgTab1.1832Diovan-HCTNOV1.18322001-03-070632160mg/25mgTab1.1832Diovan-HCTNOV1.18322003-09-040633320mg & 12.5mgTab1.1646Diovan-HCTNOV1.16462009-03-020634320mg & 25mgTab1.1646Diovan-HCTNOV1.16462009-03-02VERAPAMIL HCL0635120mgLA TabIsoptin SRABB2007-09-04Gen-Verapamil SRGEN2007-10-03Apo-Verap SRAPX2007-09-040636180mgLA Tab.5204.5204Isoptin SRABB1.44971.44971996-10-01Gen-Verapamil SRGEN.5204.52041996-10-01Apo-Verap SRAPX.5204.52042004-04-060637240mgLA Tab.6940.6940Isoptin SRABB1.93321.93321996-10-01Gen-Verapamil SRGEN.6940.69401996-10-01Novo-Veramil SRNOP.6940.69401998-12-31PMS-Verapamil SRPMS.6940.69402000-04-17Apo-Verap SRAPX.6940.69402004-04-060638180mgSR Tab.8112.8112Covera-HS (verapamil HCL) is a dosage form designed to deliver peak verapamil levels in the morning. Accordingly, Covera-HS should be administered once daily at bedtime.Covera-HSPFI.8112.81121998-12-310639240mgSR Tab.9069.9069Covera-HS (verapamil HCL) is a dosage form designed to deliver peak verapamil levels in the morning. Accordingly, Covera-HS should be administered once daily at bedtime.Covera-HSPFI.9069.90691998-12-31VASODILATING DRUGSPharmacologic tolerance (tachyphylaxis) may lead to loss of efficacy with chronic multiple (qid) daily dosing of nitrates. Continued relief of angina may require adjustment of dosage interval (e.g., tid).BETAHISTINE DIHYDROCHLORIDE064016mgTabSercSPH2007-09-04Novo-BetahistineNOP2007-09-04064124mgTabSercSPH2007-09-04Novo-BetahistineNOP2007-09-04DIPYRIDAMOLE064225mgTabPersantineBOE2009-03-02Apo-DipyridamoleAPX2009-03-02064350mgTabPersantineBOE2009-03-02Apo-DipyridamoleAPX2009-03-02064475mgTabPersantineBOE2009-03-02Apo-DipyridamoleAPX2009-03-02DIPYRIDAMOLE & ACETYLSALICYLIC ACID0645200mg/25mgCap.8230AggrenoxBOE.82302001-10-11For the secondary prevention of stroke.LU Authorization Period: Indefinite.ISOSORBIDE DINITRATE064620mgLA TabCedocard SRPMS1996-10-01Coradur-SRGLA1996-10-0106475mgSL Tab.0621Apo-ISDNAPX.06211996-10-01Isordil